[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Technicality Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":211},{"warningLetters":4,"total":210},[5,32,57,77,94,115,133,154,173,190],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},432,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-24T05:00:00Z\">11\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcdl-services-inc-dba-technichem-713877-11242025\">CDL Services, Inc. DBA Technichem \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-21\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Luis F Salazar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CDL Services, Inc. DBA Technichem \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3800 E Miraloma Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Anaheim\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-21\u003C\u002Fp>\u003Cp>November 24, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Salazar:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection at CDL Services, Inc. DBA Technichem, FEI 3012112742, located at 3080 E La Jolla Street, Anaheim, CA, from April 7 to 28, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your May 15, 2025, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) drug products including hand sanitizers and \u003Cstrong>(b)(4)\u003C\u002Fstrong> hand soap. Your firm failed to adequately test batches of your drug products for the identity and strength of your active ingredients (e.g., ethanol and chloroxylenol) before release and distribution. For example, you stated that finished product testing data provided during the inspection was generated using simulated results and that no testing had been performed on finished drug products in over a year. As a result, your firm released drug product to the market without appropriate testing, review, and approval to ensure satisfactory conformance to final specifications for strength and identity.\u003C\u002Fp>\u003Cp>In your response, you commit to testing products prior to distribution and testing the “most recently distributed” batches. Your response is inadequate in that it does not provide sufficient documentation for finished product testing (e.g., proposed test methodology or specifications). Moreover, your response fails to provide a timeline for when this testing will be completed or to perform any risk assessment.\u003C\u002Fp>\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\u003Cp>In response to this letter, provide a list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fp>\u003Cul>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug products that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure that components were suitable for use in manufacturing your OTC drug products. For example, you did not perform identity testing on each shipment of each lot of incoming components, such as glycerin, ethanol and chloroxylenol. Additionally, you relied on your suppliers’ certificates of analysis without verifying your supplier’s test results at appropriate intervals. Furthermore, you have not ensured that water used as a component is suitable for its intended use (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, United States Pharmacopeia (USP) monograph).\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ethanol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming component ethyl alcohol (ethanol) at risk of methanol contamination for identity before using it as an active pharmaceutical ingredient (API) in manufacturing your OTC topical drug products. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin and propylene glycol to determine its appropriate identity, prior to use in manufacturing your OTC topical drug products.\u003C\u002Fp>\u003Cp>Identity testing for glycerin, propylene glycol and certain other high-risk drug components includes a limit test in the USP to ensure the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Water Used as a Component in Drug Products\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Moreover, your firm uses water as a component in the manufacture of your drug products. Your firm has not demonstrated that the water is suitable for its intended use in pharmaceutical manufacturing. At a minimum, such water must meet the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph and appropriate microbial limits.\u003C\u002Fp>\u003Cp>In your response, you commit to performing identity testing of components, testing for methanol and DEG\u002FEG in high-risk components, and testing of your water used as a component. Your response is inadequate in that you did not provide a detailed plan for how your components will be assessed against compendial requirements. Furthermore, it did not include sufficient information regarding test methods or a timeline for implementing the proposed corrective actions.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the certificate of analysis (COA) from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test each incoming lot of components, including high-risk drug components, to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A commitment to provide methanol test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of methanol.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures your water system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) lacked adequate control over your OTC drug product manufacturing operations and failed to ensure that you had adequate procedures. For example, your quality unit (QU) failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of adequate procedures describing the roles and responsibilities of the QU, including review of complaints, supplier qualification, change control and periodic product quality review (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fli>\u003Cli>Establishment of appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records or other records (21 CFR 211.68(b)).\u003C\u002Fli>\u003Cli>Establishment of adequate production procedures and process control to assure your drug products have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Drug products bear expiration dates that are supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fli>\u003Cli>Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to establishing a dedicated QU with associated procedures. Your response is inadequate in that it lacks detail on systemic remediations for your QU and improvements to your quality system. Your response also fails to provide details on how your QU will have the responsibility and authority to perform its functions.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Access to Information During Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, the gas chromatograph and the associated CGMP computer system were not available to the inspection team. This limited FDA’s access to records for inspection to evaluate the CGMP compliance status of your facility.\u003C\u002Fp>\u003Cp>When an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&amp;C Act. See FDA’s guidance document \u003Cem>Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations\u003C\u002Fem> for guidance on implementing modern quality systems and risk management approaches to meet the requirements of the Agency's CGMP regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug man-ufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012112742 and ATTN: Andrew Haack, Compliance Officer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-21\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Luis F Salazar\n\nRecipient Title\n\nPresident\u002FCEO\n\nCDL Services, Inc. DBA Technichem\n\n3800 E Miraloma Avenue\n\nAnaheim, CA 92806\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-21\nNovember 24, 2025\nDear Mr. Salazar:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection at CDL Services, Inc. DBA Technichem, FEI 3012112742, located at 3080 E La Jolla Street, Anaheim, CA, from April 7 to 28, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your May 15, 2025, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm manufactures over-the-counter (OTC) drug products including hand sanitizers and (b)(4) hand soap. Your firm failed to adequately test batches of your drug products for the identity and strength of your active ingredients (e.g., ethanol and chloroxylenol) before release and distribution. For example, you stated that finished product testing data provided during the inspection was generated using simulated results and that no testing had been performed on finished drug products in over a year. As a result, your firm released drug product to the market without appropriate testing, review, and approval to ensure satisfactory conformance to final specifications for strength and identity.\nIn your response, you commit to testing products prior to distribution and testing the “most recently distributed” batches. Your response is inadequate in that it does not provide sufficient documentation for finished product testing (e.g., proposed test methodology or specifications). Moreover, your response fails to provide a timeline for when this testing will be completed or to perform any risk assessment.\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\nIn response to this letter, provide a list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug products that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm failed to ensure that components were suitable for use in manufacturing your OTC drug products. For example, you did not perform identity testing on each shipment of each lot of incoming components, such as glycerin, ethanol and chloroxylenol. Additionally, you relied on your suppliers’ certificates of analysis without verifying your supplier’s test results at appropriate intervals. Furthermore, you have not ensured that water used as a component is suitable for its intended use (e.g., (b)(4) Water, United States Pharmacopeia (USP) monograph).\nProducts Containing Ethanol\nYou failed to adequately test your incoming component ethyl alcohol (ethanol) at risk of methanol contamination for identity before using it as an active pharmaceutical ingredient (API) in manufacturing your OTC topical drug products. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nProducts Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\nYou also failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin and propylene glycol to determine its appropriate identity, prior to use in manufacturing your OTC topical drug products.\nIdentity testing for glycerin, propylene glycol and certain other high-risk drug components includes a limit test in the USP to ensure the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nWater Used as a Component in Drug Products\nMoreover, your firm uses water as a component in the manufacture of your drug products. Your firm has not demonstrated that the water is suitable for its intended use in pharmaceutical manufacturing. At a minimum, such water must meet the (b)(4) Water, USP monograph and appropriate microbial limits.\nIn your response, you commit to performing identity testing of components, testing for methanol and DEG\u002FEG in high-risk components, and testing of your water used as a component. Your response is inadequate in that you did not provide a detailed plan for how your components will be assessed against compendial requirements. Furthermore, it did not include sufficient information regarding test methods or a timeline for implementing the proposed corrective actions.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nIn response to this letter, provide:\nA summary of results obtained from testing all components to evaluate the reliability of the certificate of analysis (COA) from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical and microbiological quality control specifications you use to test each incoming lot of components, including high-risk drug components, to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA commitment to provide methanol test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of methanol.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures your water system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) lacked adequate control over your OTC drug product manufacturing operations and failed to ensure that you had adequate procedures. For example, your quality unit (QU) failed to ensure the following:\nEstablishment of adequate procedures describing the roles and responsibilities of the QU, including review of complaints, supplier qualification, change control and periodic product quality review (21 CFR 211.22(a) and 211.22(d)).\nEstablishment of appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records or other records (21 CFR 211.68(b)).\nEstablishment of adequate production procedures and process control to assure your drug products have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nDrug products bear expiration dates that are supported by appropriate stability testing (21 CFR 211.137(a)).\nEstablishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\nIn your response, you commit to establishing a dedicated QU with associated procedures. Your response is inadequate in that it lacks detail on systemic remediations for your QU and improvements to your quality system. Your response also fails to provide details on how your QU will have the responsibility and authority to perform its functions.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, include your program for qualification of your equipment and facility.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\nAccess to Information During Inspection\nDuring the inspection, the gas chromatograph and the associated CGMP computer system were not available to the inspection team. This limited FDA’s access to records for inspection to evaluate the CGMP compliance status of your facility.\nWhen an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&C Act. See FDA’s guidance document Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA. See FDA’s guidance document Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations for guidance on implementing modern quality systems and risk management approaches to meet the requirements of the Agency's CGMP regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug man-ufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012112742 and ATTN: Andrew Haack, Compliance Officer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","CDL Services, Inc. DBA Technichem","cdl-services-inc-dba-technichem-713877-11242025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcdl-services-inc-dba-technichem-713877-11242025","2026-10-26T08:08:12.259717+00:00","Warning Letter","Issued","2025-12-09","713877","Drugs Over-the-Counter Drugs","Mr. Luis F Salazar","2026-08-19T11:13:37.324+00:00","VIA UPS","320-26-21","2025-11-24",{"id":33,"raw":34,"subject":39,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":38,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":19,"reference_number":19,"action_taken_date":56,"medical_device_id":19,"response_letter_date":19},3079,[35,36,37,38,39,13,40,13],"\u003Ctime datetime=\"2021-10-19T13:20:00Z\">10\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-17T04:00:00Z\">09\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-09172021\">Magnolia Medical Technologies, Inc.\u003C\u002Fa>","Office of Medical Devices and Radiological Health, Division 3","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-05042022\">\u003Ctime datetime=\"2022-05-18T04:00:00Z\">05\u002F18\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gregory J. Bullington\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Magnolia Medical Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>200 W. Mercer Street, Suite 500\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seattle\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98119\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Greg.bullington@magnolia-medical.com\"> Greg.bullington@magnolia-medical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Devices and Radiological Health, Division 3\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 617922\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 17, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Bullington:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations at 200 W. Mercer Street, Suite 500, Seattle, WA 98119 from June 3, 2021 through July 15, 2021. During the inspection, an FDA Investigator determined that your firm is a specification developer for the Steripath Gen 2 Blood Collection System (K192247). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the Steripath Gen 2 device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s response dated August 5, 2021 concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 15, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example,\u003C\u002Fp>\n\n\u003Cp>a. Your firm’s Corrective and Preventive Action SOP, D00011, Rev. D requires your firm to track all meetings pertaining to your CAPA activities in the product investigation section of your Corrective Action Report (CAR). Your firm’s HHE-001 Closure Memo dated January 13, 2021 references meetings held to discuss CAR C00046 on October 8, 2020 and in November 2020. However, these meetings are not described or attached to your CAR C00046.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response dated August 5, 2021 and determined it is inadequate. Your firm’s response acknowledges these meetings were held and states the meeting minutes were never finalized. Your response states your CAPA procedures will be revised to clarify requirements for maintaining meeting minutes. However, your response does not identify that your firm has now finalized and included in your records the subject meeting minutes. Further, your response does not address how your firm evaluated other CARs for similar deficiencies. Lastly, we acknowledge your firm’s commitment to revise your CAPA procedures, however, there is insufficient detail of the proposed changes in your response to allow us to evaluate the adequacy at this time.\u003C\u002Fp>\n\n\u003Cp>b. Your firm’s CAPA C00046 includes an investigation conducted by your supplier of your butterfly retractable needles for premature retraction. This investigation identified three potential causes including 1) \u003Cstrong>(b)(4)\u003C\u002Fstrong>, 2) application of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization, and 3) failure to adhere to shelf-life specifications assigned by the component supplier. Your firm’s CAPA C00046 includes your firm’s evaluation of the primary cause (\u003Cstrong>(b)(4)\u003C\u002Fstrong>); however, your firm did not investigate or document your evaluation of the other potential causes.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures. Your response states your firm held several meetings to discuss these causes; however, it does not identify how you have documented and included your evaluations and investigations into these cases in your CAR C00046. Additionally, your response does not address if your firm has reviewed other CARs for similar deficiencies.\u003C\u002Fp>\n\n\u003Cp>Additionally, in your response to this letter, please also include description and records of corrective actions or evaluations conducted into the acceptance activities and purchasing controls associated with your butterfly retractable needles.\u003C\u002Fp>\n\n\u003Cp>c. Your firm initiated CAR C00050 on August 20, 2020 after identifying the bill of materials for product parts \u003Cstrong>(b)(4)\u003C\u002Fstrong> (various configurations of your Steripath Gen 2 device) contained incorrect instruction for use (IFU) designations. This CAR was closed on April 29, 2021 stating it did not qualify for a CAR because it was identified prior to implementation of the changes. However, your firm identified in October 2020, two additional lots of product (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) were manufactured and subsequently quarantined and reworked. Additionally, our inspection identified that a third lot, 9448037, was manufactured and distributed using the incorrect IFU that your firm did not identify prior to distribution. Your firm’s CAR C00050 did not include adequate investigation to identify and correct all affected products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures and has opened CAR C00073 to investigate the CAPA deficiencies. However, there is inadequate description of the proposed changes for us to evaluate the adequacy at this time. Additionally, your response does not address evaluations of other CARs to determine if similar deficiencies exist.\u003C\u002Fp>\n\n\u003Cp>d. Your firm initiated CAR C00055 on January 8, 2021 to investigate lack of implementation of changes to your Steripath Gen 2 labeling after receiving clearance for expanded indications for use. Your CAR C00055 does not include descriptions and records of your investigation into the cause of the nonconformance to ensure systemic corrective actions.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. We acknowledge you have initiated a removal for this product and your response states your firm is revising your CAPA procedures. However, your response does not address what corrective actions you are taking to specifically address CAR C00055. Additionally, your response does not address reviews of other CARs to determine if similar deficiencies exist.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures for verifying the device design to confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not conduct verification testing to support the shelf life of your Steripath Gen 2 with the butterfly needle inlet accessory.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and the “Steripath Gen2 Blood Collection Set (Needle) Configuration Shelf Life Verification Report”, D00309, Rev. A dated June 11, 2021. We cannot determine the adequacy of your response at this time. Your firm’s response states your firm will conduct a retrospective review of all verifications of your Steripath Gen 2 device to assess the impact of using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inlet accessory as the model in the testing. Additionally, your response states your firm is updating your design verification procedures to require evaluation of the inlet and outlet accessories. We request you provide updates to these activities in your response to this letter. Additionally, the provided verification report shows sections 2.4.2, 2.4.3, and 2.4.4 of the test protocol were not complete. In your response to this letter, please include an explanation of why these sections were not completed.\u003C\u002Fp>\n\n\u003Cp>3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s supplier of the butterfly needle inlet of your Steripath Gen 2 device applies a 2-year shelf life to the component. Your firm does not have manufacturing procedures to document and control the remaining shelf life of these components when used in the manufacturing of Steripath Gen 2 finished device which you apply a 2-year shelf life.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and we cannot determine the adequacy of your response at this time. Your response commits to reviewing all components of your Steripath Gen 2 device and establish procedures to monitor and control remaining shelf life at the time of manufacturing the device. In response to this letter please include updates and supporting records of implementation of these corrective actions as they progress.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Additionally, On July 7, 2021, FDA held a conference call with your firm’s Director of Operations and your firm’s Director of Quality and Regulatory to discuss concerns pertaining to your firm’s corrective actions associated with CAR C00046. During this call it was communicated to you that your firm’s CAR C00046 did not document corrective actions to address previously distributed nonconforming products. Your firm’s Director of Operations stated that a timeline of the corrective actions and the investigation addressing these concerns would be provided to the Agency. We have reviewed your firm’s memorandum dated July 12, 2021, and we do not believe the response adequately addresses those concerns. We request a conference call to further discuss your corrective actions to CAR 00046 with our Office of Medical Device and Radiological Health Operations Division 3. Please contact Compliance Officer Jeff R. Wooley to arrange a time for this call.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at \u003Cstrong>ORADevices3 FirmResponse@fda.hhs.gov\u003C\u002Fstrong>. Please identify your response with FEI 3009976527.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological\u003Cbr>\nHealth, Division 3\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGregory J. Bullington\n\nRecipient Title\n\nCEO\n\nMagnolia Medical Technologies, Inc.\n\n200 W. Mercer Street, Suite 500\n\nSeattle, WA 98119\n\nUnited States\n\nGreg.bullington@magnolia-medical.com\n\nIssuing Office:\n\nOffice of Medical Devices and Radiological Health, Division 3\n\nUnited States\n\nWARNING LETTER\n\nCMS 617922\n\nSeptember 17, 2021\n\nDear Mr. Bullington:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations at 200 W. Mercer Street, Suite 500, Seattle, WA 98119 from June 3, 2021 through July 15, 2021. During the inspection, an FDA Investigator determined that your firm is a specification developer for the Steripath Gen 2 Blood Collection System (K192247). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that the Steripath Gen 2 device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s response dated August 5, 2021 concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 15, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example,\n\na. Your firm’s Corrective and Preventive Action SOP, D00011, Rev. D requires your firm to track all meetings pertaining to your CAPA activities in the product investigation section of your Corrective Action Report (CAR). Your firm’s HHE-001 Closure Memo dated January 13, 2021 references meetings held to discuss CAR C00046 on October 8, 2020 and in November 2020. However, these meetings are not described or attached to your CAR C00046.\n\nWe have reviewed your firm’s response dated August 5, 2021 and determined it is inadequate. Your firm’s response acknowledges these meetings were held and states the meeting minutes were never finalized. Your response states your CAPA procedures will be revised to clarify requirements for maintaining meeting minutes. However, your response does not identify that your firm has now finalized and included in your records the subject meeting minutes. Further, your response does not address how your firm evaluated other CARs for similar deficiencies. Lastly, we acknowledge your firm’s commitment to revise your CAPA procedures, however, there is insufficient detail of the proposed changes in your response to allow us to evaluate the adequacy at this time.\n\nb. Your firm’s CAPA C00046 includes an investigation conducted by your supplier of your butterfly retractable needles for premature retraction. This investigation identified three potential causes including 1) (b)(4), 2) application of (b)(4) sterilization, and 3) failure to adhere to shelf-life specifications assigned by the component supplier. Your firm’s CAPA C00046 includes your firm’s evaluation of the primary cause ((b)(4)); however, your firm did not investigate or document your evaluation of the other potential causes.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures. Your response states your firm held several meetings to discuss these causes; however, it does not identify how you have documented and included your evaluations and investigations into these cases in your CAR C00046. Additionally, your response does not address if your firm has reviewed other CARs for similar deficiencies.\n\nAdditionally, in your response to this letter, please also include description and records of corrective actions or evaluations conducted into the acceptance activities and purchasing controls associated with your butterfly retractable needles.\n\nc. Your firm initiated CAR C00050 on August 20, 2020 after identifying the bill of materials for product parts (b)(4) (various configurations of your Steripath Gen 2 device) contained incorrect instruction for use (IFU) designations. This CAR was closed on April 29, 2021 stating it did not qualify for a CAR because it was identified prior to implementation of the changes. However, your firm identified in October 2020, two additional lots of product ((b)(4) and (b)(4)) were manufactured and subsequently quarantined and reworked. Additionally, our inspection identified that a third lot, 9448037, was manufactured and distributed using the incorrect IFU that your firm did not identify prior to distribution. Your firm’s CAR C00050 did not include adequate investigation to identify and correct all affected products.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures and has opened CAR C00073 to investigate the CAPA deficiencies. However, there is inadequate description of the proposed changes for us to evaluate the adequacy at this time. Additionally, your response does not address evaluations of other CARs to determine if similar deficiencies exist.\n\nd. Your firm initiated CAR C00055 on January 8, 2021 to investigate lack of implementation of changes to your Steripath Gen 2 labeling after receiving clearance for expanded indications for use. Your CAR C00055 does not include descriptions and records of your investigation into the cause of the nonconformance to ensure systemic corrective actions.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. We acknowledge you have initiated a removal for this product and your response states your firm is revising your CAPA procedures. However, your response does not address what corrective actions you are taking to specifically address CAR C00055. Additionally, your response does not address reviews of other CARs to determine if similar deficiencies exist.\n\n2. Failure to establish and maintain adequate procedures for verifying the device design to confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\n\nSpecifically, your firm did not conduct verification testing to support the shelf life of your Steripath Gen 2 with the butterfly needle inlet accessory.\n\nWe have reviewed your response dated August 5, 2021 and the “Steripath Gen2 Blood Collection Set (Needle) Configuration Shelf Life Verification Report”, D00309, Rev. A dated June 11, 2021. We cannot determine the adequacy of your response at this time. Your firm’s response states your firm will conduct a retrospective review of all verifications of your Steripath Gen 2 device to assess the impact of using the (b)(4) inlet accessory as the model in the testing. Additionally, your response states your firm is updating your design verification procedures to require evaluation of the inlet and outlet accessories. We request you provide updates to these activities in your response to this letter. Additionally, the provided verification report shows sections 2.4.2, 2.4.3, and 2.4.4 of the test protocol were not complete. In your response to this letter, please include an explanation of why these sections were not completed.\n\n3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\n\nSpecifically, your firm’s supplier of the butterfly needle inlet of your Steripath Gen 2 device applies a 2-year shelf life to the component. Your firm does not have manufacturing procedures to document and control the remaining shelf life of these components when used in the manufacturing of Steripath Gen 2 finished device which you apply a 2-year shelf life.\n\nWe have reviewed your response dated August 5, 2021 and we cannot determine the adequacy of your response at this time. Your response commits to reviewing all components of your Steripath Gen 2 device and establish procedures to monitor and control remaining shelf life at the time of manufacturing the device. In response to this letter please include updates and supporting records of implementation of these corrective actions as they progress.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nAdditionally, On July 7, 2021, FDA held a conference call with your firm’s Director of Operations and your firm’s Director of Quality and Regulatory to discuss concerns pertaining to your firm’s corrective actions associated with CAR C00046. During this call it was communicated to you that your firm’s CAR C00046 did not document corrective actions to address previously distributed nonconforming products. Your firm’s Director of Operations stated that a timeline of the corrective actions and the investigation addressing these concerns would be provided to the Agency. We have reviewed your firm’s memorandum dated July 12, 2021, and we do not believe the response adequately addresses those concerns. We request a conference call to further discuss your corrective actions to CAR 00046 with our Office of Medical Device and Radiological Health Operations Division 3. Please contact Compliance Officer Jeff R. Wooley to arrange a time for this call.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nYour response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at ORADevices3 FirmResponse@fda.hhs.gov. Please identify your response with FEI 3009976527.\n\nIf you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological\n\nHealth, Division 3","Magnolia Medical Technologies, Inc.","magnolia-medical-technologies-inc-617922-09172021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-09172021","2026-10-26T08:09:18.447816+00:00","Closed Out","2021-10-19","617922","Medical Devices","2022-05-18","Gregory J. Bullington","2026-08-20T02:31:05.728+00:00","VIA Electronic Mail","2021-09-17",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":19,"letter_url":70,"updated_at":71,"action_type":22,"case_status":23,"posted_date":72,"marcs_cms_no":73,"product_type":51,"closeout_date":19,"issuing_office":63,"recipient_name":74,"body_fetched_at":75,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},1564,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2024-03-12T13:20:00Z\">03\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-26T05:00:00Z\">01\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnobles-medical-technology-ii-inc-673465-01262024\">Nobles Medical Technology II, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Review Board (IRB)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anthony A. Nobles, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nobles Medical Technology II, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17072 Newhope Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fountain Valley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92708\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:anobles@noblesmedical.com\"> anobles@noblesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 26, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Nobles:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at Nobles Medical Technology II, Inc. from October 16, 2023, to October 20, 2023, by investigators from the FDA’s Office of Bioresearch Monitoring Operations (OBIMO). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch EL versus FDA approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent ischemic stroke,” for NobleStitch EL, Investigational Device Exemption (IDE), G180296, complied with applicable federal regulations. The NobleStitch EL is a device as that term is defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited.\u003C\u002Fp>\n\n\u003Cp>The inspection was conducted under a program designed to ensure that data and information contained in requests for IDEs, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\n\n\u003Cp>Our review of the inspection report prepared by the OBIMO revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions, which concerns requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an Inspectional Observations Form FDA-483 for your review and discussed the observations listed on the form with you. To date, your firm has not submitted a written response. The deviations noted on the Form FDA-483 and our subsequent review of the inspection report, are discussed below:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to ensure proper monitoring and Institutional Review Board (IRB) review and approval [21 CFR 812.40].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for providing investigators with the information they need to conduct the investigation properly and for ensuring proper monitoring of the investigation. You are also responsible for ensuring that IRB review and approval are obtained and that the IRB and FDA are promptly informed of significant new information about an investigation. Examples of your failure include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>a. You failed to provide investigators with necessary information to properly conduct the study, including but not limited to, signed protocols, investigational brochures, and labeling.\u003C\u002Fp>\n\n\u003Cp>b. You failed to ensure proper monitoring of the study. Examples include, but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Lack of a written monitoring plan and procedures describing how you will monitor the investigation, including how to handle protocol deviations and investigator noncompliance.\u003C\u002Fli>\n\t\u003Cli>Site monitoring reports do not include the documents reviewed, associated findings, and communications with site personnel, including whether your site monitoring included a comparison of source documents with Case Report Forms (CRFs), an essential component of a monitoring plan to ensure data integrity.\u003C\u002Fli>\n\t\u003Cli>Additionally, you failed to secure investigator signatures on CRFs in a timely manner per the Investigator Agreement Section 10.1 (Trial Documentation). For example, Investigator \u003Cstrong>(b)(6)\u003C\u002Fstrong> signed four CRFs eight to twelve months after their monitoring visits, and Investigators \u003Cstrong>(b)(6)\u003C\u002Fstrong> and \u003Cstrong>(b)(6)\u003C\u002Fstrong> did not sign nine and two CRFs, respectively, for monitoring visits to their sites.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>c. You failed to provide documentation of IRB approvals and continuing review for site \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and IRB approval for sites \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the protocol (versions 5 and 6) and the Amplatzer and NobleStitch CRFs.\u003C\u002Fp>\n\n\u003Cp>Proper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your failure to ensure that IRB review and approval was obtained at least annually, delays, or prevents the IRB from considering any changes in the research or research-related events and determining whether the human subject protection measures are adequate or need to be changed. Lastly, inadequate oversight of investigator activities can also significantly impact conduct of the study and therefore, the reliability of data generated in the study as well as the safety of study participants.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to select qualified investigators and monitors by training and experience for conducting of a study [812.43(a) and (d)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for selecting qualified investigators and monitors. Examples of your failure include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>a. You failed to ensure that clinical investigators were qualified by training and experience to conduct the study. During the inspection, you did not provide documentation, such as a curriculum vitae, to show that the clinical investigators were qualified to conduct this study.\u003C\u002Fp>\n\n\u003Cp>b. You did not provide documentation to support that you have the proper training and experience to appropriately monitor the study.\u003C\u002Fp>\n\n\u003Cp>The selection of qualified investigators and monitors is essential to ensure subjects’ safety and that your study is conducted properly in accordance with Good Clinical Practices.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to obtain a signed agreement from each participating investigator that includes a statement of the investigator’s commitment to conduct an investigation in accordance with the agreement, investigational plan, applicable FDA regulations, conditions of approval imposed by the reviewing IRB and conditions of approval imposed by the FDA [21 CFR 812.43(c)(4)(i)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for obtaining from each participating investigator a signed agreement that includes a statement of the investigator's commitment to conduct the investigation in accordance with the agreement, the investigational plan, and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB or FDA.\u003C\u002Fp>\n\n\u003Cp>While signed agreements were obtained of participating clinical investigators, they lack a statement of the investigator’s commitment to supervise all testing of the device involving human subjects. Obtaining signed agreements is important for ensuring that investigators participating in the clinical study are accountable for the conduct of the study.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to obtain from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement [21 CFR 812.43(c)(5)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor you are responsible for obtaining from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement.\u003C\u002Fp>\n\n\u003Cp>You failed to obtain a signed agreement that includes sufficient accurate financial disclosure information from each participating investigator. Specifically, you did not provide financial disclosure records for any site during your inspection. Obtaining accurate financial disclosure information is important for ensuring that there is no financial bias by any of your clinical investigators that may impact clinical study data.\u003C\u002Fp>\n\n\u003Cp>In addition to the above objectionable conditions found during the inspection of your U.S. sites, there were similar observations noted for your site in Italy, which is your largest enrolling site. These observations include inadequate study protocols, lack of investigator agreements, inadequate informed consent, inadequate adverse event reporting, inadequate investigational device tracking, and inadequate monitoring.\u003C\u002Fp>\n\n\u003Cp>All of these failures raise significant concerns regarding whether your study will yield credible and accurate data and whether the rights, safety and well-being of subjects are adequately protected. The consequences of these failures are evidenced by the decision to suspend your study and the numerous cycles of review of your annual reports for the IDE, where discrepant and unclear information has been provided regarding fundamental aspects of your study (e.g., reviewing IRBs and sites and numbers of enrolled\u002Fimplanted subjects) as well as safety and effectiveness information.\u003C\u002Fp>\n\n\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\n\n\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\u003C\u002Fp>\n\n\u003Cp>Your response should reference “CTS# G180296\u002FE003” and be sent via email to: Albert.Rodriguez@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>A copy of this letter has been sent to FDA’s OBIMO West via email ORABIMOW.Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\n\n\u003Cp>The Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, you may contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Soma Kalb, PhD\u003Cbr>\nDirector\u003Cbr>\nDivision of Clinical Policy and Quality\u003Cbr>\nOffice of Clinical Evidence &amp; Analysis\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAnthony A. Nobles, PhD\n\nRecipient Title\n\nChairman and CEO\n\nNobles Medical Technology II, Inc.\n\n17072 Newhope Street\n\nFountain Valley, CA 92708\n\nUnited States\n\nanobles@noblesmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nJanuary 26, 2024\n\nDear Dr. Nobles:\n\nThis Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at Nobles Medical Technology II, Inc. from October 16, 2023, to October 20, 2023, by investigators from the FDA’s Office of Bioresearch Monitoring Operations (OBIMO). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch EL versus FDA approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent ischemic stroke,” for NobleStitch EL, Investigational Device Exemption (IDE), G180296, complied with applicable federal regulations. The NobleStitch EL is a device as that term is defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited.\n\nThe inspection was conducted under a program designed to ensure that data and information contained in requests for IDEs, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\n\nOur review of the inspection report prepared by the OBIMO revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions, which concerns requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an Inspectional Observations Form FDA-483 for your review and discussed the observations listed on the form with you. To date, your firm has not submitted a written response. The deviations noted on the Form FDA-483 and our subsequent review of the inspection report, are discussed below:\n\n1. Failure to ensure proper monitoring and Institutional Review Board (IRB) review and approval [21 CFR 812.40].\n\nAs a sponsor, you are responsible for providing investigators with the information they need to conduct the investigation properly and for ensuring proper monitoring of the investigation. You are also responsible for ensuring that IRB review and approval are obtained and that the IRB and FDA are promptly informed of significant new information about an investigation. Examples of your failure include, but are not limited to, the following:\n\na. You failed to provide investigators with necessary information to properly conduct the study, including but not limited to, signed protocols, investigational brochures, and labeling.\n\nb. You failed to ensure proper monitoring of the study. Examples include, but are not limited to:\n\nLack of a written monitoring plan and procedures describing how you will monitor the investigation, including how to handle protocol deviations and investigator noncompliance.\n\nSite monitoring reports do not include the documents reviewed, associated findings, and communications with site personnel, including whether your site monitoring included a comparison of source documents with Case Report Forms (CRFs), an essential component of a monitoring plan to ensure data integrity.\n\nAdditionally, you failed to secure investigator signatures on CRFs in a timely manner per the Investigator Agreement Section 10.1 (Trial Documentation). For example, Investigator (b)(6) signed four CRFs eight to twelve months after their monitoring visits, and Investigators (b)(6) and (b)(6) did not sign nine and two CRFs, respectively, for monitoring visits to their sites.\n\nc. You failed to provide documentation of IRB approvals and continuing review for site (b)(4) and IRB approval for sites (b)(4) and (b)(4) for the protocol (versions 5 and 6) and the Amplatzer and NobleStitch CRFs.\n\nProper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\n\nFurthermore, your failure to ensure that IRB review and approval was obtained at least annually, delays, or prevents the IRB from considering any changes in the research or research-related events and determining whether the human subject protection measures are adequate or need to be changed. Lastly, inadequate oversight of investigator activities can also significantly impact conduct of the study and therefore, the reliability of data generated in the study as well as the safety of study participants.\n\n2. Failure to select qualified investigators and monitors by training and experience for conducting of a study [812.43(a) and (d)].\n\nAs a sponsor, you are responsible for selecting qualified investigators and monitors. Examples of your failure include, but are not limited to, the following:\n\na. You failed to ensure that clinical investigators were qualified by training and experience to conduct the study. During the inspection, you did not provide documentation, such as a curriculum vitae, to show that the clinical investigators were qualified to conduct this study.\n\nb. You did not provide documentation to support that you have the proper training and experience to appropriately monitor the study.\n\nThe selection of qualified investigators and monitors is essential to ensure subjects’ safety and that your study is conducted properly in accordance with Good Clinical Practices.\n\n3. Failure to obtain a signed agreement from each participating investigator that includes a statement of the investigator’s commitment to conduct an investigation in accordance with the agreement, investigational plan, applicable FDA regulations, conditions of approval imposed by the reviewing IRB and conditions of approval imposed by the FDA [21 CFR 812.43(c)(4)(i)].\n\nAs a sponsor, you are responsible for obtaining from each participating investigator a signed agreement that includes a statement of the investigator's commitment to conduct the investigation in accordance with the agreement, the investigational plan, and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB or FDA.\n\nWhile signed agreements were obtained of participating clinical investigators, they lack a statement of the investigator’s commitment to supervise all testing of the device involving human subjects. Obtaining signed agreements is important for ensuring that investigators participating in the clinical study are accountable for the conduct of the study.\n\n4. Failure to obtain from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement [21 CFR 812.43(c)(5)].\n\nAs a sponsor you are responsible for obtaining from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement.\n\nYou failed to obtain a signed agreement that includes sufficient accurate financial disclosure information from each participating investigator. Specifically, you did not provide financial disclosure records for any site during your inspection. Obtaining accurate financial disclosure information is important for ensuring that there is no financial bias by any of your clinical investigators that may impact clinical study data.\n\nIn addition to the above objectionable conditions found during the inspection of your U.S. sites, there were similar observations noted for your site in Italy, which is your largest enrolling site. These observations include inadequate study protocols, lack of investigator agreements, inadequate informed consent, inadequate adverse event reporting, inadequate investigational device tracking, and inadequate monitoring.\n\nAll of these failures raise significant concerns regarding whether your study will yield credible and accurate data and whether the rights, safety and well-being of subjects are adequately protected. The consequences of these failures are evidenced by the decision to suspend your study and the numerous cycles of review of your annual reports for the IDE, where discrepant and unclear information has been provided regarding fundamental aspects of your study (e.g., reviewing IRBs and sites and numbers of enrolled\u002Fimplanted subjects) as well as safety and effectiveness information.\n\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\n\nWithin 15 working days of receiving this letter, please provide documentation of the corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\n\nYour response should reference “CTS# G180296\u002FE003” and be sent via email to: Albert.Rodriguez@fda.hhs.gov.\n\nA copy of this letter has been sent to FDA’s OBIMO West via email ORABIMOW.Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\n\nThe Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn.\n\nIf you have any questions, you may contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\n\nSincerely yours,\n\n\u002FS\u002F\n\nSoma Kalb, PhD\n\nDirector\n\nDivision of Clinical Policy and Quality\n\nOffice of Clinical Evidence & Analysis\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Nobles Medical Technology II, Inc.","nobles-medical-technology-ii-inc-673465-01262024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnobles-medical-technology-ii-inc-673465-01262024","2026-10-26T08:09:34.338448+00:00","2024-03-12","673465","Anthony A. Nobles, PhD","2026-08-20T00:14:37.004+00:00","2024-01-26",{"id":78,"raw":79,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":45,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":51,"closeout_date":19,"issuing_office":63,"recipient_name":19,"body_fetched_at":92,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},3219,[80,81,82,63,83,13,13,13],"\u003Ctime datetime=\"2021-08-10T13:20:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-29T04:00:00Z\">07\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flepu-medical-technology-beijing-co-ltd-614908-07292021\">Lepu Medical Technology -Beijing- Co., Ltd.\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Lepu Medical Technology -Beijing- Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 37 Chaoqian Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Changping Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lee-fu@mid-link.net\"> lee-fu@mid-link.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: July 29, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has observed that your firm offers for sale a Neutralization Antibody Test kit (Colloidal Gold, Fluorescent, Elisa), a SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography), and a Saliva Antigen Rapid Test (hereinafter collectively referred to as “COVID-19 Test Kits”) in the United States. Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The COVID-19 Test Kits are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your COVID-19 Test Kits are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological\u003Cbr>\nHealth\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>_________________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nLepu Medical Technology -Beijing- Co., Ltd.\n\nNo. 37 Chaoqian Rd.\n\nChangping Qu\n\nBeijing Shi,\n\nChina\n\nlee-fu@mid-link.net\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: July 29, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has observed that your firm offers for sale a Neutralization Antibody Test kit (Colloidal Gold, Fluorescent, Elisa), a SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography), and a Saliva Antigen Rapid Test (hereinafter collectively referred to as “COVID-19 Test Kits”) in the United States. Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe COVID-19 Test Kits are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your COVID-19 Test Kits are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”4 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological\n\nHealth\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n_________________________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx).\n\n3 President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\n\n4 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","Lepu Medical Technology -Beijing- Co., Ltd.","lepu-medical-technology-beijing-co-ltd-614908-07292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flepu-medical-technology-beijing-co-ltd-614908-07292021","2026-10-26T08:09:13.643652+00:00","2021-08-10","614908","2026-08-20T02:42:51.907+00:00","2021-07-29",{"id":95,"raw":96,"subject":100,"body_html":101,"body_text":102,"firm_name":103,"letter_id":104,"created_at":105,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":110,"closeout_date":19,"issuing_office":11,"recipient_name":111,"body_fetched_at":112,"delivery_method":29,"recipient_title":19,"reference_number":113,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},1007,[97,98,99,11,100,13,13,13],"\u003Ctime datetime=\"2025-03-18T04:00:00Z\">03\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-14T04:00:00Z\">03\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-pharmaceutical-technology-692576-03142025\">Advanced Pharmaceutical Technology\u003C\u002Fa>","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-55\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Frank M. Bardani\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Pharmaceutical Technology\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>132 South Central Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Elmsford\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10523\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-55\u003C\u002Fp>\u003Cp>March 14, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Bardani:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Advanced Pharmaceutical Technology Inc., FEI 3009963974, at 132 South Central Avenue, Elmsford, from July 10 to August 1, 2024. The products you manufacture at this facility are combination products under section 503(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 353(g) as your products include drug and device constituent parts.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for combination products\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. See Title 21 Code of Federal Regulations (CFR) part 4, 21 CFR parts 210 and 211 (drug CGMP), and 21 CFR part 820 (Quality System or QS Regulation).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to drug CGMP requirements, 21 CFR parts 210 and 211, your combination products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, information and records gathered during the course of the inspection reflect that your products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans. Therefore, these products meet the definition of drug as defined in section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)].\u003C\u002Fp>\u003Cp>We reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. We also acknowledge that you recently registered as a 503B Outsourcing Facility. However, you have been distributing your drug products in the United States since 2023, prior to registering as a 503B Outsourcing Facility.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked appropriate controls to ensure the sterility of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products that purport to be sterile. For example, you relied on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process without monitoring pre-sterilization bioburden. In addition, you failed to establish an adequate system, as was required by your standard operating procedure (SOP), for monitoring environmental conditions (including the frequency performed) to ensure your manufacturing areas were suitable for sterile drug production.\u003C\u002Fp>\u003Cp>In your response, you state that you plan to test for bioburden, prior to release, and will reject lots that fail to meet appropriate specifications for endotoxin. You also state that environmental monitoring is not required because your drug products are \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, and that you tested product that was manufactured more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior for microbial content and the samples showed no signs of positive cultures.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to include relevant details for pre-sterilization bioburden testing, including limits you have established, and the steps you will take in the event these limits are exceeded. In addition, appropriate environmental conditions for the manufacture of your drugs, including appropriate air quality, must be provided to protect products from microbiological contamination, even when \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, in order to minimize sterilization challenges and the byproducts of excessive bioburden.\u003C\u002Fp>\u003Cp>It should be noted that although the sterility test is a critical final quality control for products that purport to be sterile, it cannot be solely relied upon as justification to release each drug product batch, as the test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Sample sizes for sterility testing are typically small compared to the total number of units in a batch and may not detect issues that result in sporadic non-sterility. For example, inadequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation studies or failure to consistently execute a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization cycle within its validated state may go undetected for substantial periods if your firm places too much reliance on the final quality control test for sterility to identify a sterility assurance problem. It is also essential to note that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and prompt review of the qualification status of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process.\u003C\u002Fp>\u003Cp>This is a repeat violation from your 2019 and 2021 inspections.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of controlled-release dosage form, appropriate laboratory determination of satisfactory conformance to the specifications for the rate of release of each active ingredient (21 CFR 211.167(c)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to provide adequate data demonstrating your drug products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have a \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the active ingredient. For example, you claim your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lasts for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products have \u003Cstrong>(b)(4)\u003C\u002Fstrong> effect for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your release and stability data for dissolution does not provide data that drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Drug products should not be released without appropriate determination of conformance to final specifications and intended use. There is a lack of assurance of appropriate quality and that your drug will have the intended effect it purports to possess.\u003C\u002Fp>\u003Cp>In your response, you state that you estimated the therapeutic duration and that you will remove \u003Cstrong>(b)(4)\u003C\u002Fstrong> claims until you perform adequate studies. Your response is inadequate because you did not provide a retrospective assessment of your drug products on the U.S. market within expiry to identify and take appropriate action on any product quality or patient safety risks.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You lacked adequate scientific rationale to demonstrate that your drug manufacturing processes are appropriately validated, reproducible, and controlled to consistently yield drug products of uniform character and quality. For example, you increased the commercial production batch size and released drug product without appropriate validation. You also failed to include critical process parameters in your batch records.\u003C\u002Fp>\u003Cp>In your response, you plan to revalidate manufacturing processes and include more detailed production steps. Your response is inadequate because you failed to provide a detailed plan or supportive documentation for adequately validating your drug production process.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>This is a repeat violation from your 2019 and 2021 inspections.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Contract Testing Laboratories\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not exercise its responsibility to oversee your contract testing laboratory to ensure the appropriate finish product testing was being conducted. For example, you failed to ensure your contract testing laboratory completed the method validation protocol for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Method Validation Report did not identify potential impurities of \u003Cstrong>(b)(4)\u003C\u002Fstrong> referenced in the method validation protocol. You did not adequately ensure the executed test method was suitable to monitor all potential impurities.\u003C\u002Fp>\u003Cp>In your response, you provided an impurity method that did not adequately identify and characterize the potential impurities of your drug products. Your response is inadequate because the method validation protocol should include all potential impurities with the scientific justification for which ones would be included in the test method. You did not commit to performing a retrospective assessment of all the product lots currently on the market within expiry once new method validations are completed.\u003C\u002Fp>\u003Cp>In addition, your contract testing laboratory was conducting a single dissolution test point for your drug products without scientific justification that a single time point demonstrates a consistent drug absorption over an extended period of time.\u003C\u002Fp>\u003Cp>Your response states that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> label claims were removed. Your response is inadequate because you did not provide sufficient scientific justification to support inadequately testing your finished drug product.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See the FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Contract Manufacturing Organizations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm utilizes a contract manufacturing organization (CMO) to manufacture your prescription sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated to our investigators that you received a batch of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You received this drug product without performing an evaluation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You do not have adequate procedures to ensure that the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> produced for your firm met appropriate quality attributes.\u003C\u002Fp>\u003Cp>In your response, you provide documentation indicating that the CMO of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong> and provided documentation of an audit performed at this facility. Your response is inadequate because your QU did not ensure the drug product was manufactured in accordance with CGMP requirements.\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&amp;C Act, 21 U.S.C. 374(a)(4) to your CMO of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection USP), \u003Cstrong>(b)(4)\u003C\u002Fstrong>. After multiple follow-up requests, your CMO failed to respond to these attempted communications or otherwise provide the requested records or other information. It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your CMO failed to respond to the section 704(a)(4) records requests and associated communication attempts, FDA placed all drugs and drug products manufactured by your CMO on Import Alert 66-79. Drugs manufactured by facilities on Import Alert 66-79 are subject to refusal of admission pursuant to section 801(a)(3) of the FD&amp;C Act in that all drugs from their facility appear to be adulterated under section 501(j) because they have been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as your \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection product are listed in FDA’s electronic Drug Registration and Listing System (eDRLS) as “Export Only.” However, information obtained during the inspection of your firm indicates that your firm plans to distribute these products commercially in the United States. Please be advised that, based on review of the product labeling collected during the inspection of your firm and the labeling that your firm submitted to FDA’s eDRLS, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act and require FDA premarket approval under section 505 of the FD&amp;C Act [21 U.S.C. 355]. Distribution of an unapproved new drug in the United States is prohibited under section 301(d) of the FD&amp;C Act [21 U.S.C. 331(d)].\u003C\u002Fp>\u003Cp>We encourage you to contact FDA’s Office of New Drugs at ONDCommunications@fda.hhs.gov for assistance with the application process for your unapproved drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>503B Registration\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FD&amp;C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FD&amp;C Act [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements in section 582 of the FD&amp;C Act [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FD&amp;C Act are met. However, outsourcing facilities must comply with other applicable provisions of the FD&amp;C Act, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding CGMP requirements.\u003Cem>\u003Cstrong>\u003Csup>2,3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Manufactured for Importation into the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drug products imported into the United States must comply with all applicable requirements under the FD&amp;C Act and the corresponding regulations set forth in Title 21 of the Code of Federal Regulations. These requirements include compliance with labeling requirements, firm registration and drug listing, and adherence to CGMP. Facilities that manufacture drug products and drug components intended for importation into the United States are subject to inspection by the FDA to determine compliance with these regulatory standards. For drugs requiring NDA or ANDA approval, the application must be submitted to and approved by the FDA’s Center for Drug Evaluation and Research (CDER) prior to importation, as required by section 505(a) of the FD&amp;C Act and 21 CFR part 314.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Manufactured for Exportation out of the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drug products exported from the United States under section 802 of the FD&amp;C Act, must comply with applicable requirements under the FD&amp;C Act, including those specified in section 802(f) [21 U.S.C. § 382(f)]. Under this provision, a drug may not be exported if it is not “manufactured, processed, packaged, and held in substantial conformity with current good manufacturing practice requirements.” Furthermore, a drug is considered adulterated under section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] if the methods, facilities, or controls used in its manufacture, processing, packaging, or holding do not conform to CGMP standards.\u003C\u002Fp>\u003Cp>We therefore encourage you to review your manufacturing processes to ensure that unapproved new drugs intended for export comply with CGMP requirements. Non-compliance with these requirements prevents your ability to export these drugs under section 802(f) of the FD&amp;C Act [21 U.S.C. § 382(f)].\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In previous inspections from September 10 to 27, 2019, and August 5 to 23, 2021, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009963974 and ATTN: Kevin Maguire.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Jill P. Furman\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>The terms combination product and drug are used interchangeably in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> For additional information, please see FDA’s “Information for Outsourcing Facilities” webpage, available at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Finformation-outsourcing-facilities. Furthermore, FDA’s Compounding Quality Center Of Excellence (CQCOE) supports outsourcing facilities’ efforts to improve the quality of drugs they produce through training, research and engagement activities with FDA and other supporting stakeholders. For additional information on the CQCOE, please visit https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fcompounding-quality-center-excellence.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-55\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Frank M. Bardani\n\nRecipient Title\n\nPresident\n\nAdvanced Pharmaceutical Technology\n\n132 South Central Avenue\n\nElmsford, NY 10523\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-55\nMarch 14, 2025\nDear Mr. Bardani:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Advanced Pharmaceutical Technology Inc., FEI 3009963974, at 132 South Central Avenue, Elmsford, from July 10 to August 1, 2024. The products you manufacture at this facility are combination products under section 503(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 353(g) as your products include drug and device constituent parts.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for combination products1. See Title 21 Code of Federal Regulations (CFR) part 4, 21 CFR parts 210 and 211 (drug CGMP), and 21 CFR part 820 (Quality System or QS Regulation).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to drug CGMP requirements, 21 CFR parts 210 and 211, your combination products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nIn addition, information and records gathered during the course of the inspection reflect that your products, (b)(4), are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans. Therefore, these products meet the definition of drug as defined in section 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)].\nWe reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. We also acknowledge that you recently registered as a 503B Outsourcing Facility. However, you have been distributing your drug products in the United States since 2023, prior to registering as a 503B Outsourcing Facility.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.113(b)).\nYou lacked appropriate controls to ensure the sterility of (b)(4) drug products that purport to be sterile. For example, you relied on the (b)(4) sterilization process without monitoring pre-sterilization bioburden. In addition, you failed to establish an adequate system, as was required by your standard operating procedure (SOP), for monitoring environmental conditions (including the frequency performed) to ensure your manufacturing areas were suitable for sterile drug production.\nIn your response, you state that you plan to test for bioburden, prior to release, and will reject lots that fail to meet appropriate specifications for endotoxin. You also state that environmental monitoring is not required because your drug products are (b)(4) sterilized, and that you tested product that was manufactured more than (b)(4) prior for microbial content and the samples showed no signs of positive cultures.\nYour response is inadequate because you failed to include relevant details for pre-sterilization bioburden testing, including limits you have established, and the steps you will take in the event these limits are exceeded. In addition, appropriate environmental conditions for the manufacture of your drugs, including appropriate air quality, must be provided to protect products from microbiological contamination, even when (b)(4) sterilized, in order to minimize sterilization challenges and the byproducts of excessive bioburden.\nIt should be noted that although the sterility test is a critical final quality control for products that purport to be sterile, it cannot be solely relied upon as justification to release each drug product batch, as the test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Sample sizes for sterility testing are typically small compared to the total number of units in a batch and may not detect issues that result in sporadic non-sterility. For example, inadequate (b)(4) sterilization validation studies or failure to consistently execute a (b)(4) sterilization cycle within its validated state may go undetected for substantial periods if your firm places too much reliance on the final quality control test for sterility to identify a sterility assurance problem. It is also essential to note that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and prompt review of the qualification status of your (b)(4) sterilization process.\nThis is a repeat violation from your 2019 and 2021 inspections.\n2. Your firm failed to have, for each batch of controlled-release dosage form, appropriate laboratory determination of satisfactory conformance to the specifications for the rate of release of each active ingredient (21 CFR 211.167(c)).\nYou failed to provide adequate data demonstrating your drug products, (b)(4), have a (b)(4) of the active ingredient. For example, you claim your (b)(4) lasts for up to (b)(4) and that your (b)(4) products have (b)(4) effect for (b)(4). Your release and stability data for dissolution does not provide data that drug (b)(4). Drug products should not be released without appropriate determination of conformance to final specifications and intended use. There is a lack of assurance of appropriate quality and that your drug will have the intended effect it purports to possess.\nIn your response, you state that you estimated the therapeutic duration and that you will remove (b)(4) claims until you perform adequate studies. Your response is inadequate because you did not provide a retrospective assessment of your drug products on the U.S. market within expiry to identify and take appropriate action on any product quality or patient safety risks.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm manufactures (b)(4) sterilized, (b)(4). You lacked adequate scientific rationale to demonstrate that your drug manufacturing processes are appropriately validated, reproducible, and controlled to consistently yield drug products of uniform character and quality. For example, you increased the commercial production batch size and released drug product without appropriate validation. You also failed to include critical process parameters in your batch records.\nIn your response, you plan to revalidate manufacturing processes and include more detailed production steps. Your response is inadequate because you failed to provide a detailed plan or supportive documentation for adequately validating your drug production process.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nThis is a repeat violation from your 2019 and 2021 inspections.\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nContract Testing Laboratories\nYour quality unit (QU) did not exercise its responsibility to oversee your contract testing laboratory to ensure the appropriate finish product testing was being conducted. For example, you failed to ensure your contract testing laboratory completed the method validation protocol for (b)(4). The Method Validation Report did not identify potential impurities of (b)(4) referenced in the method validation protocol. You did not adequately ensure the executed test method was suitable to monitor all potential impurities.\nIn your response, you provided an impurity method that did not adequately identify and characterize the potential impurities of your drug products. Your response is inadequate because the method validation protocol should include all potential impurities with the scientific justification for which ones would be included in the test method. You did not commit to performing a retrospective assessment of all the product lots currently on the market within expiry once new method validations are completed.\nIn addition, your contract testing laboratory was conducting a single dissolution test point for your drug products without scientific justification that a single time point demonstrates a consistent drug absorption over an extended period of time.\nYour response states that the (b)(4) label claims were removed. Your response is inadequate because you did not provide sufficient scientific justification to support inadequately testing your finished drug product.\nYour firm’s quality systems are inadequate. See the FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nContract Manufacturing Organizations\nYour firm utilizes a contract manufacturing organization (CMO) to manufacture your prescription sterile (b)(4) drug product, (b)(4). You stated to our investigators that you received a batch of (b)(4) from (b)(4). You received this drug product without performing an evaluation of (b)(4). You do not have adequate procedures to ensure that the sterile (b)(4) produced for your firm met appropriate quality attributes.\nIn your response, you provide documentation indicating that the CMO of (b)(4) is (b)(4) and provided documentation of an audit performed at this facility. Your response is inadequate because your QU did not ensure the drug product was manufactured in accordance with CGMP requirements.\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nFDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4) to your CMO of (b)(4) Injection USP), (b)(4). After multiple follow-up requests, your CMO failed to respond to these attempted communications or otherwise provide the requested records or other information. It is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your CMO failed to respond to the section 704(a)(4) records requests and associated communication attempts, FDA placed all drugs and drug products manufactured by your CMO on Import Alert 66-79. Drugs manufactured by facilities on Import Alert 66-79 are subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that all drugs from their facility appear to be adulterated under section 501(j) because they have been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nUnapproved Drugs\nYour (b)(4) products, (b)(4), as well as your (b)(4) injection product are listed in FDA’s electronic Drug Registration and Listing System (eDRLS) as “Export Only.” However, information obtained during the inspection of your firm indicates that your firm plans to distribute these products commercially in the United States. Please be advised that, based on review of the product labeling collected during the inspection of your firm and the labeling that your firm submitted to FDA’s eDRLS, these products are new drugs within the meaning of section 201(p) of the FD&C Act and require FDA premarket approval under section 505 of the FD&C Act [21 U.S.C. 355]. Distribution of an unapproved new drug in the United States is prohibited under section 301(d) of the FD&C Act [21 U.S.C. 331(d)].\nWe encourage you to contact FDA’s Office of New Drugs at ONDCommunications@fda.hhs.gov for assistance with the application process for your unapproved drug products.\n503B Registration\nUnder section 503B(b) of the FD&C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FD&C Act [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements in section 582 of the FD&C Act [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FD&C Act are met. However, outsourcing facilities must comply with other applicable provisions of the FD&C Act, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding CGMP requirements.2,3\nDrugs Manufactured for Importation into the United States\nDrug products imported into the United States must comply with all applicable requirements under the FD&C Act and the corresponding regulations set forth in Title 21 of the Code of Federal Regulations. These requirements include compliance with labeling requirements, firm registration and drug listing, and adherence to CGMP. Facilities that manufacture drug products and drug components intended for importation into the United States are subject to inspection by the FDA to determine compliance with these regulatory standards. For drugs requiring NDA or ANDA approval, the application must be submitted to and approved by the FDA’s Center for Drug Evaluation and Research (CDER) prior to importation, as required by section 505(a) of the FD&C Act and 21 CFR part 314.\nDrugs Manufactured for Exportation out of the United States\nDrug products exported from the United States under section 802 of the FD&C Act, must comply with applicable requirements under the FD&C Act, including those specified in section 802(f) [21 U.S.C. § 382(f)]. Under this provision, a drug may not be exported if it is not “manufactured, processed, packaged, and held in substantial conformity with current good manufacturing practice requirements.” Furthermore, a drug is considered adulterated under section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] if the methods, facilities, or controls used in its manufacture, processing, packaging, or holding do not conform to CGMP standards.\nWe therefore encourage you to review your manufacturing processes to ensure that unapproved new drugs intended for export comply with CGMP requirements. Non-compliance with these requirements prevents your ability to export these drugs under section 802(f) of the FD&C Act [21 U.S.C. § 382(f)].\nRepeat Violations at Facility\nIn previous inspections from September 10 to 27, 2019, and August 5 to 23, 2021, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nCGMP Consultant Recommended\nBecause you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009963974 and ATTN: Kevin Maguire.\nSincerely,\n\u002FS\u002F\nJill P. Furman\nDirector\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________\n1 The terms combination product and drug are used interchangeably in this letter.\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FD&C Act.\n3 For additional information, please see FDA’s “Information for Outsourcing Facilities” webpage, available at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Finformation-outsourcing-facilities. Furthermore, FDA’s Compounding Quality Center Of Excellence (CQCOE) supports outsourcing facilities’ efforts to improve the quality of drugs they produce through training, research and engagement activities with FDA and other supporting stakeholders. For additional information on the CQCOE, please visit https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fcompounding-quality-center-excellence.","Advanced Pharmaceutical Technology","advanced-pharmaceutical-technology-692576-03142025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-pharmaceutical-technology-692576-03142025","2026-10-26T08:07:50.58707+00:00","2025-03-18","692576","Drugs","Mr. Frank M. Bardani","2026-08-19T16:55:57.953+00:00","320-25-55","2025-03-14",{"id":116,"raw":117,"subject":121,"body_html":122,"body_text":123,"firm_name":124,"letter_id":125,"created_at":45,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":51,"closeout_date":19,"issuing_office":63,"recipient_name":130,"body_fetched_at":131,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":132,"medical_device_id":19,"response_letter_date":19},3276,[118,119,120,63,121,13,13,13],"\u003Ctime datetime=\"2021-07-06T13:20:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-04T04:00:00Z\">06\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzhejiang-xichen-medical-technology-co-ltd-612946-06042021\">Zhejiang Xichen Medical Technology Co., Ltd.\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yinlong Dong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Zhejiang Xichen Medical Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2nd Floor, 3 Building, No. 6, Lvyuan Zhong Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Quzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>324000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:xs2@xicengroup.com\"> xs2@xicengroup.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Xichen001@aliyun.com\"> Xichen001@aliyun.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: June 4, 2021\u003Cbr>\n\u003Cbr>\nRe: “FFP2 NR 5-Layer KN95 Face Mask,” “Medical Face Mask,” and “Sterile Surgical Mask”\u003C\u002Fp>\n\n\u003Cp>Dear Yinlong Dong:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the internet address https:\u002F\u002Fwww.xichen-med.com\u002F on March 23, 2021. The FDA has observed that your website offers the “FFP2 NR 5-Layer KN95 Face Mask,” “Medical Face Mask,” and “Sterile Surgical Mask” for sale in the United States. Based on our review, these products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h). We also note that the FFP2 NR 5-Layer KN95 Face Mask is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people.\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, including but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Representing the FFP2 NR 5-Layer KN95 Face Mask as a “COVID-19 Respirator” with “effective antibacterial” properties for use to “prevent…bacteria, droplets and other harmful particles,” “filter germs,” and provide “protection for your family” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fffp2-nr-5-layer-kn95-face-mask.html]\u003Cbr>\n• Representing the Medical Face Mask for use to “prevent infection,” “protect patients and other persons from the transmission of pathogenic microorganisms, body fluids, particulate matter, etc., especially in the event of an epidemic or pandemic,” and provide “protection for your family” as well as offering a “bacterial filtration efficiency [of] &gt; 98%” and “microbial cleanliness [of] &lt;30CFY\u002Fg” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fdisposable-mask.html]\u003Cbr>\n• Representing the Sterile Surgical Mask as a “Medical Surgical Mask” that is “antibacterial” and provides a “BFE above 95%” for use to “prevent the spread of body fluids and body splash content and isolate dust, particle [sic], alcohol, blood, bacteria, and virus invading.” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fsterile-surgical-mask.html]\u003C\u002Fp>\n\n\u003Cp>The FFP2 NR 5-Layer KN95 Face Mask, Medical Face Mask, and Sterile Surgical Mask (each of which your website indicates is manufactured by Zhejiang Xichen Medical Technology Co. Ltd) are offered for sale in the United States without marketing approval, clearance, or authorization from the FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, the FFP2 NR 5-Layer KN95 Face Mask is misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false or misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Displaying a “FDA REGISTRATION CERTIFICATE” also referred to as the “kn95-FDA Certificate” issued by “J &amp; F Technology Services LLC” (Certificate) under the “About Us” tab on your website. The Certificate certifies that “Zhejiang Xichen Medical Technology Co., Ltd…has completed the FDA Establishment Registration (as manufacturer, foreign exporter, contract manufacturer) and Device Listing with the US Food &amp; Drug Administration.” The Certificate has the look of an official government document, incorporating unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and an illustration of an eagle and a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.xichen-med.com\u002Four-certificate]\u003Cbr>\n• Displaying a screenshot titled “kn-95-Registration information is available on the FDA website” of what appears to be Zhejiang Xichen Medical Technology Co., Ltd.’s previous entry in FDA’s Establishment Registration &amp; Device Listing Database. [https:\u002F\u002Fwww.xichen-med.com\u002Four-certificate]\u003C\u002Fp>\n\n\u003Cp>Taken together, display of the Certificate, bearing the FDA logo, and a screenshot from FDA’s Establishment Registration &amp; Device Listing Database positioned near images of and information about the FFP2 NR 5-Layer KN95 Face Mask are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Zhejiang Xichen Medical Technology Co., Ltd. is or was registered with the FDA and that the firm is or was in possession of a registration number. Although the Certificate appears to be intended to function as a disclaimer, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificate. We also note that you seem to reference the Certificate or some other certificate on the Sterile Surgical Mask’s webpage [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fsterilesurgical-mask.html], indicating the product has a “Certificate CE, FDA.” These representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database merely denotes that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID -19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 612946 or CTS Number CPT2001023 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector\u003Cbr>\nDivision of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>US Agent: Fanny Zhao\u003Cbr>\nJ &amp; F Technology Services LLC\u003Cbr>\n2424 Morris Ave 818\u003Cbr>\nUnion, New Jersey 07083\u003Cbr>\nEmail Address: info@jf-yiliao.com\u003C\u002Fp>\n\n\u003Cp>Contact: Yucai.qiu\u003Cbr>\nXICEN International Gmb\u003Cbr>\nGlobal Office Center, Beethovenstr. 5\u003Cbr>\nDE-60325 Frankfurt\u002FM,Germany\u003Cbr>\nEmail Address: yucai.qiu@xicengroup.com\u003C\u002Fp>\n\n\u003Cp>XICEN International Corporation\u003Cbr>\n245 E. Main Street, Suite 107\u003Cbr>\nAlhambra, California, 91801\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nYinlong Dong\n\nZhejiang Xichen Medical Technology Co., Ltd.\n\n2nd Floor, 3 Building, No. 6, Lvyuan Zhong Road\n\nQuzhou Shi\n\nZhejiang Sheng, 324000\n\nChina\n\nxs2@xicengroup.com\n\nXichen001@aliyun.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: June 4, 2021\n\nRe: “FFP2 NR 5-Layer KN95 Face Mask,” “Medical Face Mask,” and “Sterile Surgical Mask”\n\nDear Yinlong Dong:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the internet address https:\u002F\u002Fwww.xichen-med.com\u002F on March 23, 2021. The FDA has observed that your website offers the “FFP2 NR 5-Layer KN95 Face Mask,” “Medical Face Mask,” and “Sterile Surgical Mask” for sale in the United States. Based on our review, these products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h). We also note that the FFP2 NR 5-Layer KN95 Face Mask is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people.\n\nFDA’s review of your website revealed the following statements that establish that the products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, including but not limited to:\n\n• Representing the FFP2 NR 5-Layer KN95 Face Mask as a “COVID-19 Respirator” with “effective antibacterial” properties for use to “prevent…bacteria, droplets and other harmful particles,” “filter germs,” and provide “protection for your family” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fffp2-nr-5-layer-kn95-face-mask.html]\n\n• Representing the Medical Face Mask for use to “prevent infection,” “protect patients and other persons from the transmission of pathogenic microorganisms, body fluids, particulate matter, etc., especially in the event of an epidemic or pandemic,” and provide “protection for your family” as well as offering a “bacterial filtration efficiency [of] > 98%” and “microbial cleanliness [of] \u003C30CFY\u002Fg” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fdisposable-mask.html]\n\n• Representing the Sterile Surgical Mask as a “Medical Surgical Mask” that is “antibacterial” and provides a “BFE above 95%” for use to “prevent the spread of body fluids and body splash content and isolate dust, particle [sic], alcohol, blood, bacteria, and virus invading.” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fsterile-surgical-mask.html]\n\nThe FFP2 NR 5-Layer KN95 Face Mask, Medical Face Mask, and Sterile Surgical Mask (each of which your website indicates is manufactured by Zhejiang Xichen Medical Technology Co. Ltd) are offered for sale in the United States without marketing approval, clearance, or authorization from the FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, the FFP2 NR 5-Layer KN95 Face Mask is misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. 21 CFR 807.39.\n\nYour website contains a number of false or misleading representations, including but not limited to:\n\n• Displaying a “FDA REGISTRATION CERTIFICATE” also referred to as the “kn95-FDA Certificate” issued by “J & F Technology Services LLC” (Certificate) under the “About Us” tab on your website. The Certificate certifies that “Zhejiang Xichen Medical Technology Co., Ltd…has completed the FDA Establishment Registration (as manufacturer, foreign exporter, contract manufacturer) and Device Listing with the US Food & Drug Administration.” The Certificate has the look of an official government document, incorporating unauthorized use of the FDA logo2 and an illustration of an eagle and a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.xichen-med.com\u002Four-certificate]\n\n• Displaying a screenshot titled “kn-95-Registration information is available on the FDA website” of what appears to be Zhejiang Xichen Medical Technology Co., Ltd.’s previous entry in FDA’s Establishment Registration & Device Listing Database. [https:\u002F\u002Fwww.xichen-med.com\u002Four-certificate]\n\nTaken together, display of the Certificate, bearing the FDA logo, and a screenshot from FDA’s Establishment Registration & Device Listing Database positioned near images of and information about the FFP2 NR 5-Layer KN95 Face Mask are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Zhejiang Xichen Medical Technology Co., Ltd. is or was registered with the FDA and that the firm is or was in possession of a registration number. Although the Certificate appears to be intended to function as a disclaimer, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificate. We also note that you seem to reference the Certificate or some other certificate on the Sterile Surgical Mask’s webpage [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fsterilesurgical-mask.html], indicating the product has a “Certificate CE, FDA.” These representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database merely denotes that the establishment has provided certain information to FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID -19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 612946 or CTS Number CPT2001023 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector\n\nDivision of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nUS Agent: Fanny Zhao\n\nJ & F Technology Services LLC\n\n2424 Morris Ave 818\n\nUnion, New Jersey 07083\n\nEmail Address: info@jf-yiliao.com\n\nContact: Yucai.qiu\n\nXICEN International Gmb\n\nGlobal Office Center, Beethovenstr. 5\n\nDE-60325 Frankfurt\u002FM,Germany\n\nEmail Address: yucai.qiu@xicengroup.com\n\nXICEN International Corporation\n\n245 E. Main Street, Suite 107\n\nAlhambra, California, 91801\n\n_________________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Zhejiang Xichen Medical Technology Co., Ltd.","zhejiang-xichen-medical-technology-co-ltd-612946-06042021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzhejiang-xichen-medical-technology-co-ltd-612946-06042021","2026-10-26T08:10:39.291136+00:00","2021-07-06","612946","Yinlong Dong","2026-08-20T03:00:14.241+00:00","2021-06-04",{"id":134,"raw":135,"subject":139,"body_html":140,"body_text":141,"firm_name":142,"letter_id":143,"created_at":144,"fei_number":19,"letter_url":145,"updated_at":146,"action_type":22,"case_status":23,"posted_date":147,"marcs_cms_no":148,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":149,"body_fetched_at":150,"delivery_method":151,"recipient_title":19,"reference_number":152,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},22203,[136,137,138,11,139,13,13,13],"\u003Ctime datetime=\"2026-11-10T05:00:00Z\">11\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-29T04:00:00Z\">10\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026\">Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fa>","Refusal to Provide Access to and Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-15\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jianyu Zhao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Firm Contact\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-2066, No 88 HuanHe South Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Free Trade Pilot Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>KongGang Economic Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Shi\u003C\u002Fspan>, \u003Cspan>300000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 29, 2026\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-15\u003C\u002Fp>\u003Cp>To Jianyu Zhao:\u003C\u002Fp>\u003Cp>This warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>Your facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>A review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\u003C\u002Fp>\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Refusal to Provide Records\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant \u003Cstrong>(b)(4)\u003C\u002Fstrong> products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\u003C\u002Fp>\u003Cp>Simply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\u003C\u002Fp>\u003Cp>If you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\u003Cp>In response to this letter, you may submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: U.S. agent\u003Cbr>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-15\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJianyu Zhao\n\nRecipient Title\n\nFirm Contact\n\nTianjin Healthcare Medical Technology Co., Ltd.\n\n2-2066, No 88 HuanHe South Road\n\nTianjin Free Trade Pilot Zone\n\nKongGang Economic Zone\n\nTianjin Shi, 300000\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 29, 2026\n\nWARNING LETTER\nReference number: 320-27-15\nTo Jianyu Zhao:\nThis warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\nYour facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\nA review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\nRefusal to Provide Records\nOn June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant (b)(4) products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\nSimply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\nFDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\nIf you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\nConclusion\nThe violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\nUntil FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\nIn response to this letter, you may submit a request to schedule an FDA inspection.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: U.S. agent\n(b)(6)","Tianjin Healthcare Medical Technology Co., Ltd.","tianjin-healthcare-medical-technology-co-ltd-736415-10292026","2026-11-17T01:02:03.701861+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026","2026-11-17T01:02:49.409207+00:00","2026-11-10","736415","Jianyu Zhao","2026-11-17T01:02:49.249+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-15","2026-10-29",{"id":155,"raw":156,"subject":160,"body_html":161,"body_text":162,"firm_name":163,"letter_id":164,"created_at":165,"fei_number":19,"letter_url":166,"updated_at":167,"action_type":22,"case_status":23,"posted_date":168,"marcs_cms_no":169,"product_type":51,"closeout_date":19,"issuing_office":63,"recipient_name":170,"body_fetched_at":171,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":172,"medical_device_id":19,"response_letter_date":19},702,[157,158,159,63,160,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-11T04:00:00Z\">07\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-kerbio-medical-technology-group-co-705188-07112025\">Jiangsu Kerbio Medical Technology Group Co.\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Shangyou Lin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer, General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jiangsu Kerbio Medical Technology Group Co.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Chang yang Rd., No. 9, C4 Building\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wujin Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Changzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>, \u003Cspan>213145\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@jcssmt.com\"> contact@jcssmt.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 11, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Lin:\u003C\u002Fp>\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the United States Food and Drug Administration (FDA) inspection conducted at Jiangsu Kerbio Medical Technology Group Co. from January 15, 2025, to January 24, 2025, by investigators from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI) Foreign Inspection Cadre. This inspection was conducted to determine whether activities and procedures related to your participation in Good Laboratory Practice (GLP) nonclinical studies complied with applicable federal regulations. Specifically, FDA investigators focused on the list of studies below including, but not limited to, guinea pig maximization sensitization (GPMT), acute systemic toxicity (AST), rabbit pyrogen, muscle implantation, hemolysis, and cytotoxicity tests conducted at your facility.\u003C\u002Fp>\u003Cp>The list of studies below is not an all-inclusive list of studies impacted by the inspection or by the violations cited in this letter.\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>Study Number\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Test\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Guinea Pig Maximization Sensitization Test (GPMT)\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Acute Systemic Toxicity (AST)\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Rabbit Pyrogen\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Hemolysis\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Muscle Implantation Test 4 and 13 Weeks\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>MTT Cytotoxicity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>These tests are used in nonclinical studies for the development of devices as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>The inspection was conducted under a program designed to ensure that data and information contained in requests for Investigational Device Exemption, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\u003Cp>Our review of the inspection report prepared by the OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies, which concerns, among other things, requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). Compliance with Part 58 is intended to assure the quality and integrity of the safety data filed in a premarket submission. At the close of the inspection, the FDA investigators presented the inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you.\u003C\u002Fp>\u003Cp>We received a response from your firm dated February 21, 2025, concerning our investigators’ observations noted on the Form FDA-483. We address this response below, in relation to each of the noted violations. This letter requests prompt corrective action to address the violations cited and discusses your written response dated February 21, 2025, to the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. The study director failed to assure that (1) the protocol, including any change, is approved as provided by § 58.120 and is followed; (2) all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified; and (3) all applicable good laboratory practice regulations are followed [21 CFR 58.33(a), (b), and (e)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The study director has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation and reporting of results, and represents the single point of study control. The study director’s responsibilities include assuring that studies are conducted in accordance with the protocol, all experimental data are accurately recorded and verified, and that applicable GLP regulations are followed. Examples of the study director’s failures to adhere to these requirements include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-028 states that, “The study personnel should fill out the animal observation records in the corresponding experimental records daily.” However, based on the study records reviewed by the FDA investigators for GPMT and intracutaneous reactivity studies, there were no daily animal observations raw data included in the experimental records. Documentation of animal observations in study records is necessary to allow for the reconstruction and evaluation of the final study reports. Without these records, it is not possible to confirm that these observations, which are critical to the interpretation and analysis of study results, indeed occurred, and that the final study reports accurately reflect what was observed at the time of testing.\u003C\u002Fp>\u003Cp>b. The raw data for multiple studies conducted by two different study directors showed that the same person reportedly conducted two separate study related activities at the same or overlapping times. Additionally, the raw data for multiple studies showed that other study personnel were reportedly using the same equipment at the same time. This indicates that all experimental data were not accurately recorded and verified. Examples of discrepancies are as follows:\u003C\u002Fp>\u003Cp>1. In two intracutaneous reactivity studies, the same study personnel, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, reportedly shaved all three rabbits for study \u003Cstrong>(b)(4)\u003C\u002Fstrong> and weighed all three rabbits for study \u003Cstrong>(b)(4)\u003C\u002Fstrong> at exactly 17:19 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It appears implausible that the same study personnel could shave and weigh multiple rabbits from two separate studies at the exact same time.\u003C\u002Fp>\u003Cp>2. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, study personnel, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, completed weighing \u003Cstrong>(b)(4)\u003C\u002Fstrong> guinea pigs for the GMPT study \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> while study personnel, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, also completed weighing \u003Cstrong>(b)(4)\u003C\u002Fstrong> animals for GMPT study \u003Cstrong>(b)(4)\u003C\u002Fstrong> at 9:12 both using scale \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The data suggests that either these two study activities were conducted at overlapping times using the same equipment or that \u003Cstrong>(b)(4)\u003C\u002Fstrong> animals were weighed within the span of two minutes, both of which appear implausible.\u003C\u002Fp>\u003Cp>c. On January 21, 2025, one of the FDA investigators directly observed study personnel, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, retroactively completing records for an ongoing subacute systemic toxicity study, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including clinical observations and animal weight data from Day 1 of the study up to Day 26 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of the study. When asked to provide documentation that animals for this study were weighed, the records provided later that day showed that the animal weight data were incomplete as week 2 only included 5 out of 20 animal weights, and there were no weights recorded for week 3 which should have been completed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Failure to accurately record and verify experimental data as per the study protocol undermines the integrity and reliability of the study.\u003C\u002Fp>\u003Cp>d. Raw data records for ten intracutaneous reactivity studies conducted in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and two that were conducted in \u003Cstrong>(b)(4)\u003C\u002Fstrong> (refer to the table below) included an animal reuse record (document #\u003Cstrong>(b)(4)\u003C\u002Fstrong>32 Version 3.2) indicating that the studies utilized rabbits that had been previously used in other studies. This contradicts the study protocols (see protocol Section 4: Animal Care and Maintenance for each respective study) which indicate that, “Only healthy, previously unused animals were selected.”\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>e. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-030 Skin Sensitization Test (Guinea pig maximization test) requires that guinea pigs shall be acclimatized for at least 5 days. However, the study records for GPMT studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> show that this SOP was not followed. The study records documented that these studies were initiated on the guinea pigs three days after the animals were received. For example, study \u003Cstrong>(b)(4)\u003C\u002Fstrong> was started on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and according to the Animal Quality Certificate, the animal was purchased on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, study \u003Cstrong>(b)(4)\u003C\u002Fstrong> was started on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the animal was purchased on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>As the principal point of study control, the study director did not assure that studies were conducted in accordance with the protocol, that all experimental data were accurately recorded and verified, and that applicable good laboratory practice regulations were followed. When the protocol is not followed, data is erroneously recorded or analyzed, or other unforeseen circumstances occur that negatively affect the data, important findings in the study may be overlooked and the data cannot be accurately interpreted. Failure to follow the protocol impacts the quality and reliability of data contained within the final study report. This adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a marketed device or for the purposes of beginning clinical trials, as applicable. Furthermore, failure to ensure accurate data such as individual animal weights, animal preparation, observations, and results, yields questionable study results and conclusions. Based on these failures, FDA has concerns about the quality and integrity of the data generated from the nonclinical laboratory studies conducted at your testing facility. Complete and accurate study data are necessary to allow FDA to fully assess the overall safety and risk of a device with an associated premarket submission. The unreliable data raises concerns about the quality and integrity of associated premarket submissions, which may put public health and safety at risk. Additionally, lack of daily observation of individual animals directly impacts the overall study integrity, as it is unclear if the animals are malnourished or sick in any way, which would have a direct impact on the interpretation of the study results\u003C\u002Fp>\u003Cp>Your written response is inadequate. The written response you provided states that the relevant standard operating procedures (SOPs) that address the concerns noted in the Form 483 will be revised and a GLP working group will be established to implement a regulatory compliance improvement plan for 21 CFR Part 58. However, the updated SOPs were not included in your response, and it is unclear whether you plan to retrain personnel on the updated SOPs.\u003C\u002Fp>\u003Cp>Additionally, your firm stated that you will conduct trainings on FDA 21 CFR Part 58 regulations to ensure thorough understanding of the compliance requirements but did not provide copies of the training materials. Given the deviations and issues cited in the violations, it is necessary to review the training materials to determine their adequacy for the trained individuals to both conduct the tests per the standards being used, and to produce accurate, traceable results.\u003C\u002Fp>\u003Cp>Furthermore, your response does not provide assurance that these violations will not occur again. Specifically, your response did not: (1) detail how your testing facility will assure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; (2) address any planned preventive actions such as frequency (i.e., quarterly, annual) of audits to check for compliance or future training of new study directors, as applicable; and (3) detail how appropriate documentation\u002Ffollow-up will be ensured when deviations arise in the future. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Your explanation, when taken into consideration with the violations described above, which occurred in multiple studies with various study directors over many months, suggests systemic failures in study director oversight of nonclinical laboratory studies and brings into question the quality and integrity of safety data collected at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish procedures for a system for the handling of the test and control articles to ensure that (1) proper identification is maintained throughout the distribution process and (2) the receipt and distribution of each batch is documented. Such documentation shall include the date and quantity of each batch distributed or returned [21 CFR 58.107(c) and (d)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your failures to adhere to this requirement include, but are not limited to, the following examples:\u003C\u002Fp>\u003Cp>a. Verification of the lot\u002Fbatch number was not found to be documented during sample receipt, preparation, or on any other source data records.\u003C\u002Fp>\u003Cp>b. Your firm’s Sample Information Form - \u003Cstrong>(b)(4)\u003C\u002Fstrong>052 listed the sample quantity received for study \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Safety Intravenous Needles for Single Use) as “3 packs” with no record of how many needles were in each pack. The form then lists 1 and ¼ of a pack were distributed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. The same amounts were then listed as returned on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. The form goes on to list that \"3 packs\" were disposed of on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There was no record of the number of needles used and returned.\u003C\u002Fp>\u003Cp>c. Your firm’s sample preparation form \u003Cstrong>(b)(4)\u003C\u002Fstrong>83 does not require verification or documentation of the lot number or quantity of needles used for extraction for GPMT testing.\u003C\u002Fp>\u003Cp>d. The investigators found 12 GLP studies (refer to table below) where, after completion of the testing, the study director made changes to the test article information (indicated in bold in the table) or updated the test article photo (indicated by [1] in the table) in the final study report at the sponsor's request. These changes included revisions to the test article lot #, material, and size information, suggesting that proper identification is not maintained throughout the distribution process.\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>Study\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Number: \"SSMT-S\"\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Test article per protocol:\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Studies\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Completed:\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Change\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Request date:\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Test article per final study report:\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>\u003Cem>1\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fem>The photo of the test article in the final report is not the same as the one in the protocol.\u003C\u002Fp>\u003Cp>Failure to have established procedures for the handling of the test and control articles to ensure that proper identification of the articles is maintained and that the receipt and distribution of each batch are documented as required by the regulations creates the potential for errors to occur during handling such that the incorrect information could be attributed to the article under study. This in turn could lead to testing discrepancies and inaccurate test results and conclusions. In addition, lack of these procedures adversely impacts the traceability of the test samples, reliability of the testing, and the manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials, as applicable.\u003C\u002Fp>\u003Cp>Your written response is inadequate. The written response you provided states that the relevant standard operating procedures (SOPs) addressing the concerns noted in the Form 483 will be revised, and GLP experts will be invited to provide training on FDA GLP and 510(k) regulations.\u003C\u002Fp>\u003Cp>However, your response did not: (1) include copies of revised SOPs \u003Cstrong>(b)(4)\u003C\u002Fstrong>-002 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>-003 and (2) provide details regarding the proposed trainings, including information on the types of personnel that will undergo the trainings, training materials that will be used, and how the effectiveness of the training will be evaluated. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide assurance that these violations will not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure of the Quality Assurance Unit (QAU) to inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection and to bring any problems found during the course of an inspection which are likely to affect study integrity to the attention of the study director and management immediately [21 CFR 58.35(b)(3)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>GLP regulations require that QAU inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection showing the date of the inspection, the study inspected, the phase or segment of the study inspected, the person performing the inspection, findings and problems, action recommended and taken to resolve existing problems, and any scheduled date for reinspection. Any problems found during the course of an inspection which are likely to affect study integrity shall be brought to the attention of the study director and management immediately. Examples of the QAU’s failures include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. The QAU failed to identify any of the data irregularities, errors, and omissions that were observed by FDA, including those described in the examples of failures throughout this letter.\u003C\u002Fp>\u003Cp>b. There were 67 studies reviewed during the inspection, of which 63 were conducted from 2023-2024. For these 63 studies, the final study reports include a signature attesting that the QAU audited the protocol, raw data, and final study reports. However, records did not support that all reported audits were completed at the reported times. Examples are as follows:\u003C\u002Fp>\u003Cp>1. Only three (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) out of the 63 covered studies had record of a raw data audit per the QA inspection summary reports.\u003C\u002Fp>\u003Cp>2. Thirty out of the 63 covered studies did not have the reported final study report audits included on the QA inspection summary reports.\u003C\u002Fp>\u003Cp>3. Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, completed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was observed to have an error within the printed cassette labels; however, there was no deviation or record of when this error was discovered or that it had been reported to the study director. The FDA investigators found the final report for this study was still in draft form but included the quality assurance statement reporting QAU inspections of the study protocol on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the raw data and final study report on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, when asked to provide copies of those QA audit reports, your firm only provided a copy of a QAU inspection report for the study protocol which was dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This audit report was not recorded on the QA Summary Report of Inspections. These discrepancies, including differences between the protocol audit date recorded in the quality assurance statement of the draft study report versus in the QAU inspection report, along with the missing audit report for the final study report and raw data, and lack of related audits mentioned in the QA Summary Report of Inspections, indicate a lack of adequate monitoring by the QAU.\u003C\u002Fp>\u003Cp>A reliable QAU is integral to the successful understanding and completion of any GLP study. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report are accurate and valid. Failure to perform QAU functions, such as monitoring studies to ensure protocols were followed and data are accurately recorded, over the course of multiple studies also calls into question the quality and integrity of studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response included a document that outlines your QAU’s review of QA statements, corresponding QA inspection reports, and Summary of Inspection Report for the final study reports reviewed by the FDA investigators. You also indicated in your response that the relevant SOPs addressing the concerns noted in the Form 483 will be revised along with Form QAU-F002 “Summary of Inspection Report”, interviews will be conducted with QA personnel to clarify responsibilities, a gap analysis of the existing quality management system will be conducted, and a working group will be established to identify existing problems and make improvements. Additionally, you stated plans to have training provided by an external GLP expert. However, your response did not: (1) include copies of the revised SOPs and form such that the adequacy of the revisions can be assessed and (2) provide details regarding the proposed trainings, including the training materials that will be used and how the effectiveness of the training will be evaluated. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide reasonable assurance that QAU failures will be avoided in the future.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure of a testing facility to have standard operating procedures in writing setting forth nonclinical laboratory study methods that management is satisfied are adequate to ensure the quality and integrity of the data generated in the course of a study. The study director failed to authorize all deviations in the study from standard operating procedures and ensure the deviations were documented in the raw data [21 CFR 58.81(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>SOPs should be adequate to ensure the quality and integrity of data generated in a study. However, not all SOPs appear to be adequate. The study director also must authorize all deviations from SOPs in a study and document all study deviations in the raw data. However, the study directors at your testing facility did not adhere to these requirements. Deviations from standard operating procedures in a study also were not authorized by the study director and documented in the raw data. Examples of these issues include the following:\u003C\u002Fp>\u003Cp>a. Your firm was found to be operating under two sets of SOPs for conducting the same types of tests. One was originated for conducting testing per domestic standards and the more recent set is referred to as your GLP SOPs. There were no instructions directing which SOPs were to be used for any given study. FDA investigators found conflicting instructions between your firm’s \"domestic\" study procedures and your \"GLP\" procedures. For example, the domestic SOP, SOP-\u003Cstrong>(b)(4)\u003C\u002Fstrong>02 Animal Clinical Observation requires the use of four separate forms (\u003Cstrong>(b)(4)\u003C\u002Fstrong>: General clinical observation during study, \u003Cstrong>(b)(4)\u003C\u002Fstrong>: Detailed clinical observation during study, \u003Cstrong>(b)(4)\u003C\u002Fstrong>: General clinical observation during quarantine, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>: Detailed clinical observation during quarantine) to record clinical observations separately while animals are in quarantine versus on study. However, the corresponding GLP SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-028 only requires one form to document clinical observations while animals are in quarantine (\u003Cstrong>(b)(4)\u003C\u002Fstrong>: Animal Reception, Animal Receipt, Distribution and Quarantine Records) and does not have any requirement to use certain forms for documenting observations while on study. The lack of appropriate forms to document observations in your “GLP” procedures indicates the inadequacy of your SOPs to ensure the quality and integrity of data generated. Additionally, the GLP SOP states that, “The study personnel should fill out the animal observation records in the corresponding experimental records daily.” However, as described under violation 1 of this letter, it does not appear that daily animal observations were being recorded in accordance with this SOP. This deviation from the SOP does not appear to be authorized by the study directors nor documented in the raw data.\u003C\u002Fp>\u003Cp>b. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-028: “Animal clinical observation and management of abnormal conditions” does not include any information on signs of abnormal conditions based on species, though GLP studies were conducted on mice, rats, and rabbits. Lack of sufficient detail within this SOP could lead to errors in identifying abnormal conditions exhibited by study animals which in turn could directly impact the quality and integrity of the data generated in the course of the studies.\u003C\u002Fp>\u003Cp>c. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-030: “Skin Sensitization Test (Guinea Pig Maximization Test)” does not include adequate instructions for clinical observation of the animals during the studies, such as assuring that their breathing is not restricted when wrapping them with the occlusive dressings during the challenge and induction phases and that animals undergo observation daily to ensure isolation and treatment of any wounds or illness throughout the study. Additionally, the SOP and training materials for the GPMT test lacked photos to demonstrate how to use the Magnusson Kligman scores. Clinical observations are essential to the quality and integrity of the data generated from this testing, and this SOP was found to lack sufficient detail to ensure that tests can be conducted reliably and consistently.\u003C\u002Fp>\u003Cp>Failure of a testing facility to have adequate SOPs, or follow established SOPs if adequate, in multiple studies with multiple study directors over many months suggests systemic failures in the operation of your nonclinical laboratory. This failure raises questions about the reliability and accuracy of the data and does not ensure the quality and integrity of data generated in a study. Failing to follow SOPs and having inadequate SOPs yield inadequate protocols that introduce ambiguity and uncertainty as to how study requirements are to be followed, as well as inconsistent execution of studies and unreliable study results. Any deviations from the SOPs must be authorized by the study director and documented in the raw data. Failure to properly document any authorized deviations could result in study data with a high level of variability that challenges the ability to effectively interpret the study results associated with a device. This in turn adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials, if applicable.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response acknowledged the observations cited and indicated that the relevant SOPs addressing the concerns noted in the Form 483 will be revised, a gap analysis of the existing quality management system will be conducted, and an external GLP expert will be engaged to perform an audit. However, the response did not: (1) include copies of the revised SOPs such that the adequacy of the revisions can be assessed (2) describe plans for retraining personnel on revised SOPs (3) detail how your testing facility will ensure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; (4) address any planned preventive actions such as frequency (i.e., quarterly, annual) of audits to check for compliance or future training of new study directors, as applicable; and (5) detail how appropriate documentation\u002Ffollow-up will be ensured when deviations arise in the future. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your written response does not provide assurance that similar violations would not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure of the testing facility to ensure that all newly received animals from outside sources were isolated and their health status evaluated in accordance with acceptable veterinary medical practice [21 CFR 58.90(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>All newly received animals should be isolated and evaluated to determine health status. This can allow for early detection of potential health issues. Your failures to adhere to this requirement include, but are not limited to, the following examples:\u003C\u002Fp>\u003Cp>a. The FDA investigators reviewed guinea pig receiving and quarantine records totaling five months during 2023 and 2024. The records documented that the firm received over \u003Cstrong>(b)(4)\u003C\u002Fstrong> guinea pigs in these five months and all these guinea pigs were recorded as \"normal\" or \"okay\" with no deaths reported while in quarantine. This seems highly implausible as there were six deaths among 903 animals in the guinea pig quarantine room \u003Cstrong>(b)(4)\u003C\u002Fstrong> over a two-day period that occurred during the inspection.\u003C\u002Fp>\u003Cp>b. Your firm’s records indicate on at least one occasion while still conducting GLP rabbit studies, you received more rabbits than you have the capacity to isolate for the required time. For example, 180 New Zealand White Rabbits were received on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and these rabbits were reportedly held under quarantine from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, according to your firm, the capacity across all designated rabbit quarantine rooms in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> building (\u003Cstrong>(b)(4)\u003C\u002Fstrong> in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> building) is 141 rabbits.\u003C\u002Fp>\u003Cp>Your records raise significant concerns regarding your isolation procedures as well as your evaluation of the status of test animals. Failure to isolate newly received animals or evaluate the animal’s health status can raise serious concerns about the validity of study data. Animals may be sick upon arrival. If transferred to housing with other test animals already enrolled in another study, the newly received test animal could make the other test animals sick and impact study results. Further, test animals must be free of any disease or condition that might interfere at the beginning of a study or may significantly impact study data and\u002For results.\u003C\u002Fp>\u003Cp>Your firm’s failure to have adequate intake and isolation procedures for test animals arriving at your facility suggests systemic failures in your firm’s nonclinical laboratory practices. Further, failures that relate to test animals used in numerous studies raises questions about the quality and integrity of data collected at your facility.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response includes revising SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-002, issuing death reports for the six guinea pig deaths identified during the inspection, and converting Room \u003Cstrong>(b)(4)\u003C\u002Fstrong> in Building \u003Cstrong>(b)(4)\u003C\u002Fstrong> into a rabbit quarantine room, adding \u003Cstrong>(b)(4)\u003C\u002Fstrong> cages to comply with company standards. However, your response does not include: (1) copies of the revised SOP such that the adequacy of the revisions can be assessed, (2) documentation that addresses the changes to the rabbit quarantine room by adding additional cages to accommodate the animals more efficiently, and (3) documentation that demonstrates the special training for QAU personnel on SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-002 procedures was conducted and Quality Assurance Manager roles and responsibilities have been established. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Your explanation, when taken into consideration with the violations described above, which occurred over many months, suggests systemic failure in study director and veterinarian oversight of nonclinical laboratory studies and brings into question data integrity and animal care and welfare at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure of the testing facility to ensure warm-blooded animals, excluding suckling rodents, used in laboratory procedures that require manipulations and observations over an extended period of time or in studies that require the animals to be removed from and returned to their home cages for any reason (e.g., cage cleaning, treatment, etc.) received appropriate identification [21 CFR 58.90(d)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your failures to adhere to this requirement include, but are not limited to, the following example:\u003C\u002Fp>\u003Cp>a. Your firm does not use unique or study-specific animal identification numbers to prevent mix-ups during studies that require animals be removed from their cages for study related procedures including weighing and assessments. For example, for 11 GPMT studies started on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and completed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and 14 GPMT studies started on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and completed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the polar negative control group animals for each study are all identified as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and the non-polar vehicle controls are “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” All the test animals for each study are numbered “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for the polar and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for the non-polar. The records the FDA investigators reviewed indicated your firm has assessed and weighed guinea pigs with identical IDs from multiple studies concurrently, in the same room, and on the same scale.\u003C\u002Fp>\u003Cp>Failure to appropriately identify each animal by ensuring that they are identified with unique, study-specific identification numbers raises concerns about lack of traceability of the specific animal in the cage to the test and\u002For to the results of the testing presented in the reports. The inability to distinguish the test animals and control animals across different studies raises serious concerns about the validity of the test results. Since the ability to identify specific animals is foundational to being able to draw scientifically valid conclusions from the studies, the accuracy of study results cannot be verified.\u003C\u002Fp>\u003Cp>Your written response does not adequately address the issue of misidentification. Your written response includes revising the SOP (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-002) to enforce unique animal identification numbers. It also includes revising test records for guinea pig studies to add unique ID numbers to ensure data traceability and the recruitment of external GLP experts to train staff on FDA 21 CFR Part 58. However, your response does not include copies of the revised SOP such that the adequacy of the revisions can be assessed, written documentation of the GLP training information, nor does it discuss the specific personnel that will undergo the future GLP training and\u002For newly implemented procedures as applicable. Given the deviations and issues cited in the violations above, it is necessary to review the training materials to determine their adequacy for the trained individuals to both conduct the tests per the standards being used, and to produce accurate, traceable results. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your written response does not provide assurance that misidentification of animals would not reoccur.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to provide a separate laboratory space, as needed, for the performance of the routine and specialized procedures required by nonclinical laboratory studies [21 CFR 58.49].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A testing facility must provide separate laboratory space for routine and specialized procedures required by nonclinical laboratory studies, as needed. This requirement ensures that studies are conducted in a controlled environment and that potentially hazardous materials or procedures are isolated from other operations. Your failures to adhere to this requirement include, but are not limited to, the following examples:\u003C\u002Fp>\u003Cp>a. According to your firm’s floor plan for Building \u003Cstrong>(b)(4)\u003C\u002Fstrong>, rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are listed as a “Procedure Room” and “Anteroom” respectively, with \u003Cstrong>(b)(4)\u003C\u002Fstrong> connecting to Guinea Pig Room \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> connecting to Guinea Pig Room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, study director \u003Cstrong>(b)(6)\u003C\u002Fstrong> indicated that Rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are shared as the procedure rooms for both rabbits and guinea pigs for rabbit intracutaneous reactivity studies and for guinea pig sensitization studies, respectively. Not only are they shared space for different species, according to your firm’s floor plan, these two rooms are connected, not separate. Maintaining proper separation of species or test systems is a requirement per 21 CFR 58.43(a)(1).\u003C\u002Fp>\u003Cp>b. During the inspection, it was found that scale \u003Cstrong>(b)(4)\u003C\u002Fstrong>-494 located in one of the rabbit pyrogen rooms, is shared for measuring weights of both rabbits and guinea pig species. It was also found that your firm does not have procedures for cleaning the room or equipment between studies of different species, as required per 21 CFR 58.81(b)(11).\u003C\u002Fp>\u003Cp>c. There is inadequate space in both rabbit pyrogen test rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to conduct the procedures that are required for this test. Per the United States Pharmacopeia (USP) &lt;151&gt; Pyrogenicity Test standard for the rabbit pyrogen test, it should be conducted in a separate area designated solely for pyrogen testing and under environmental conditions that are free from disturbances likely to excite the rabbits. According to study director \u003Cstrong>(b)(6)\u003C\u002Fstrong>, due to the limited space in the rooms, rabbits are transferred one at a time from the rabbit feeding rooms and put on the restrainers. This opening and closing the doors causes repeated disturbances to the rabbits already transferred to the pyrogen room as they await testing. In addition, there is extremely limited space for personnel to move around or to conduct procedures on the rabbits without disturbing the others.\u003C\u002Fp>\u003Cp>Separation of animal species during biomedical testing is important to prevent interspecies disease transmission, minimize potential anxiety and behavioral changes due to conflict, and ensure the reliability of experimental results. The presence of multiple intermixed species can introduce confounding factors into in vivo testing, making it difficult to isolate the effects of a specific treatment or intervention, which impacts data integrity. Minimizing additional stress in terms of designating adequate laboratory space for procedures and housing is also important for the health and welfare of the study animals.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response included an explanation of the planned corrections, including: (1) dedicating rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> to performing guinea pig studies only, (2) reducing the number of rabbit pyrogen tests in rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure the number of test items matches the facility’s capacity, (3) transferring of some pyrogen testing to the backup laboratory to comply with USP &lt;151&gt;, and (4) revising SOPs \u003Cstrong>(b)(4)\u003C\u002Fstrong>-014 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>-002.\u003C\u002Fp>\u003Cp>However, the response did not provide the following: (1) objective evidence that the appropriate SOPs have been revised, and (2) documentation that addresses the changes to the designation of different testing rooms to accommodate the animals more efficiently. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. In addition, your response stated that priority was given to completing a volume of studies over GLP compliance, which resulted in insufficient space to assure proper adherence to regulatory requirements. This suggests that these issues are systemic and brings into question the quality and integrity of the laboratory operation areas and data collected at your testing facility. Therefore, your response does not provide assurance that these violations will not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>8. Failure of the Quality Assurance Unit (QAU) to maintain a copy of a master schedule sheet of all nonclinical laboratory studies conducted at the testing facility indexed by test article and containing the test system, nature of study, date study was initiated, current status of each study, identity of the sponsor, and name of the study director [21 CFR 58.35(b)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your failures to adhere to this requirement include, but are not limited, to the following examples:\u003C\u002Fp>\u003Cp>a. There was no master schedule (MS) prior to February 12, 2022, but your firm has been conducting GLP studies since at least April 2020. Moreover, the MS does not include the sponsor or test system.\u003C\u002Fp>\u003Cp>b. Per your SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-014, the test facility manager is responsible for maintaining the master schedule, not the QAU.\u003C\u002Fp>\u003Cp>c. In addition, the FDA investigators found the following completed GLP studies were archived but were not included on the master schedule: \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Without a complete and accurate MS, the study director and QAU would not know which studies are underway, at which stages and when inspections or audits are indicated. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report are accurate and valid. Failure to perform QAU functions can have a negative impact on a study because it indicates a lack of oversight to ensure compliance with all applicable GLP regulations and calls into question the quality and integrity of studies conducted.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response attributes these failures to inadequate planning and insufficient training to ensure that GLP requirements are fully understood. You propose to correct the MS to include all GLP studies conducted from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to present. Your corrective action includes revising “SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-013 Project Acceptance, Distribution of Project Numbers, Assignment of Project Leaders, and Management of Master Plan Forms,” among other actions. However, it does not provide documentation that the appropriate SOPs have been revised. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide assurances that QAU failures will be avoided in the future.\u003C\u002Fp>\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your facility. It is your responsibility as a non-clinical laboratory to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\u003Cp>FDA acknowledges that your written response dated February 21, 2025, included a signed letter stating that “…due to the increasingly intense price competition within the domestic market, our institution has become unsustainable to support the basic costs associated with full system compliance. This presents significant long-term challenges and risks to our institution, as well as potential product quality risks for our customers. As a result, we hereby affirm that, effective immediately, we will suspend all FDA-related non-clinical testing for a minimum period of three years, until December 31, 2027.” Furthermore, you state that, “In the event that our company decides to resume FDA-related non-clinical testing services after January 1, 2028, we commit to the following:\u003C\u002Fp>\u003Cul>\u003Cli>Submitting a formal notification to the FDA at least six (6) months prior to any planned resumption of services, detailing our operational readiness and compliance measures.\u003C\u002Fli>\u003Cli>Resuming services only after obtaining written authorization from the FDA and ensuring alignment with current regulatory expectations.\u003C\u002Fli>\u003Cli>Ensuring that all activities are conducted in full compliance with the FDA’s most recent regulatory requirements, quality standards, and inspection protocols in effect at the time of resumption.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the additional corrective and preventive actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the testing facility. Any submitted corrective action plan should include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. In addition, please provide a complete list of all nonclinical laboratory studies of FDA-regulated devices for the last five years, including the name of the study, the test article, the name of the study director and sponsor, and the current status of the study. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you. In addition, FDA could initiate disqualification proceedings against you in accordance with 21 CFR 58.202. If you believe that you have complied with the FD&amp;C Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your response should reference “CTS# EC250079\u002FE001” and be sent via email to: Irfan.Khan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>A copy of this letter has been sent to FDA’s OBMI Foreign Inspection Cadre via email FDAInternationalBIMO@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Angela Dixon-Allamby, by phone at (301) 796-5548 or email at Angela.Dixon-Allamby@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Soma Kalb, PhD\u003Cbr>Director\u003Cbr>DCEA1: Division of Clinical Policy and Quality\u003Cbr>Office of Clinical Evidence &amp; Analysis\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Shangyou Lin\n\nRecipient Title\n\nChief Executive Officer, General Manager\n\nJiangsu Kerbio Medical Technology Group Co.\n\nChang yang Rd., No. 9, C4 Building\n\nWujin Qu\n\nChangzhou Shi\n\nJiangsu Sheng, 213145\n\nChina\n\ncontact@jcssmt.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nJuly 11, 2025\nDear Mr. Lin:\nThis Warning Letter is to inform you of objectionable conditions observed during the United States Food and Drug Administration (FDA) inspection conducted at Jiangsu Kerbio Medical Technology Group Co. from January 15, 2025, to January 24, 2025, by investigators from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI) Foreign Inspection Cadre. This inspection was conducted to determine whether activities and procedures related to your participation in Good Laboratory Practice (GLP) nonclinical studies complied with applicable federal regulations. Specifically, FDA investigators focused on the list of studies below including, but not limited to, guinea pig maximization sensitization (GPMT), acute systemic toxicity (AST), rabbit pyrogen, muscle implantation, hemolysis, and cytotoxicity tests conducted at your facility.\nThe list of studies below is not an all-inclusive list of studies impacted by the inspection or by the violations cited in this letter.\nStudy NumberTest\n(b)(4)Intracutaneous Reactivity\n(b)(4)Guinea Pig Maximization Sensitization Test (GPMT)\n(b)(4)Acute Systemic Toxicity (AST)\n(b)(4)Rabbit Pyrogen\n(b)(4)Hemolysis\n(b)(4)Muscle Implantation Test 4 and 13 Weeks\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)MTT Cytotoxicity\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n\nThese tests are used in nonclinical studies for the development of devices as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThe inspection was conducted under a program designed to ensure that data and information contained in requests for Investigational Device Exemption, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\nOur review of the inspection report prepared by the OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies, which concerns, among other things, requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). Compliance with Part 58 is intended to assure the quality and integrity of the safety data filed in a premarket submission. At the close of the inspection, the FDA investigators presented the inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you.\nWe received a response from your firm dated February 21, 2025, concerning our investigators’ observations noted on the Form FDA-483. We address this response below, in relation to each of the noted violations. This letter requests prompt corrective action to address the violations cited and discusses your written response dated February 21, 2025, to the noted violations. These violations include, but are not limited to, the following:\n1. The study director failed to assure that (1) the protocol, including any change, is approved as provided by § 58.120 and is followed; (2) all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified; and (3) all applicable good laboratory practice regulations are followed [21 CFR 58.33(a), (b), and (e)].\nThe study director has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation and reporting of results, and represents the single point of study control. The study director’s responsibilities include assuring that studies are conducted in accordance with the protocol, all experimental data are accurately recorded and verified, and that applicable GLP regulations are followed. Examples of the study director’s failures to adhere to these requirements include, but are not limited to, the following:\na. SOP (b)(4)-028 states that, “The study personnel should fill out the animal observation records in the corresponding experimental records daily.” However, based on the study records reviewed by the FDA investigators for GPMT and intracutaneous reactivity studies, there were no daily animal observations raw data included in the experimental records. Documentation of animal observations in study records is necessary to allow for the reconstruction and evaluation of the final study reports. Without these records, it is not possible to confirm that these observations, which are critical to the interpretation and analysis of study results, indeed occurred, and that the final study reports accurately reflect what was observed at the time of testing.\nb. The raw data for multiple studies conducted by two different study directors showed that the same person reportedly conducted two separate study related activities at the same or overlapping times. Additionally, the raw data for multiple studies showed that other study personnel were reportedly using the same equipment at the same time. This indicates that all experimental data were not accurately recorded and verified. Examples of discrepancies are as follows:\n1. In two intracutaneous reactivity studies, the same study personnel, (b)(6), reportedly shaved all three rabbits for study (b)(4) and weighed all three rabbits for study (b)(4) at exactly 17:19 on (b)(4). It appears implausible that the same study personnel could shave and weigh multiple rabbits from two separate studies at the exact same time.\n2. On (b)(4), study personnel, (b)(6), completed weighing (b)(4) guinea pigs for the GMPT study (b)(4) at (b)(4) while study personnel, (b)(6), also completed weighing (b)(4) animals for GMPT study (b)(4) at 9:12 both using scale (b)(4). The data suggests that either these two study activities were conducted at overlapping times using the same equipment or that (b)(4) animals were weighed within the span of two minutes, both of which appear implausible.\nc. On January 21, 2025, one of the FDA investigators directly observed study personnel, (b)(6), retroactively completing records for an ongoing subacute systemic toxicity study, (b)(4), including clinical observations and animal weight data from Day 1 of the study up to Day 26 ((b)(4)) of the study. When asked to provide documentation that animals for this study were weighed, the records provided later that day showed that the animal weight data were incomplete as week 2 only included 5 out of 20 animal weights, and there were no weights recorded for week 3 which should have been completed on (b)(4). Failure to accurately record and verify experimental data as per the study protocol undermines the integrity and reliability of the study.\nd. Raw data records for ten intracutaneous reactivity studies conducted in (b)(4) and two that were conducted in (b)(4) (refer to the table below) included an animal reuse record (document #(b)(4)32 Version 3.2) indicating that the studies utilized rabbits that had been previously used in other studies. This contradicts the study protocols (see protocol Section 4: Animal Care and Maintenance for each respective study) which indicate that, “Only healthy, previously unused animals were selected.”\n(b)(4)\ne. SOP (b)(4)-030 Skin Sensitization Test (Guinea pig maximization test) requires that guinea pigs shall be acclimatized for at least 5 days. However, the study records for GPMT studies (b)(4) and (b)(4) show that this SOP was not followed. The study records documented that these studies were initiated on the guinea pigs three days after the animals were received. For example, study (b)(4) was started on (b)(4), and according to the Animal Quality Certificate, the animal was purchased on (b)(4). In addition, study (b)(4) was started on (b)(4), and the animal was purchased on (b)(4).\nAs the principal point of study control, the study director did not assure that studies were conducted in accordance with the protocol, that all experimental data were accurately recorded and verified, and that applicable good laboratory practice regulations were followed. When the protocol is not followed, data is erroneously recorded or analyzed, or other unforeseen circumstances occur that negatively affect the data, important findings in the study may be overlooked and the data cannot be accurately interpreted. Failure to follow the protocol impacts the quality and reliability of data contained within the final study report. This adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a marketed device or for the purposes of beginning clinical trials, as applicable. Furthermore, failure to ensure accurate data such as individual animal weights, animal preparation, observations, and results, yields questionable study results and conclusions. Based on these failures, FDA has concerns about the quality and integrity of the data generated from the nonclinical laboratory studies conducted at your testing facility. Complete and accurate study data are necessary to allow FDA to fully assess the overall safety and risk of a device with an associated premarket submission. The unreliable data raises concerns about the quality and integrity of associated premarket submissions, which may put public health and safety at risk. Additionally, lack of daily observation of individual animals directly impacts the overall study integrity, as it is unclear if the animals are malnourished or sick in any way, which would have a direct impact on the interpretation of the study results\nYour written response is inadequate. The written response you provided states that the relevant standard operating procedures (SOPs) that address the concerns noted in the Form 483 will be revised and a GLP working group will be established to implement a regulatory compliance improvement plan for 21 CFR Part 58. However, the updated SOPs were not included in your response, and it is unclear whether you plan to retrain personnel on the updated SOPs.\nAdditionally, your firm stated that you will conduct trainings on FDA 21 CFR Part 58 regulations to ensure thorough understanding of the compliance requirements but did not provide copies of the training materials. Given the deviations and issues cited in the violations, it is necessary to review the training materials to determine their adequacy for the trained individuals to both conduct the tests per the standards being used, and to produce accurate, traceable results.\nFurthermore, your response does not provide assurance that these violations will not occur again. Specifically, your response did not: (1) detail how your testing facility will assure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; (2) address any planned preventive actions such as frequency (i.e., quarterly, annual) of audits to check for compliance or future training of new study directors, as applicable; and (3) detail how appropriate documentation\u002Ffollow-up will be ensured when deviations arise in the future. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Your explanation, when taken into consideration with the violations described above, which occurred in multiple studies with various study directors over many months, suggests systemic failures in study director oversight of nonclinical laboratory studies and brings into question the quality and integrity of safety data collected at your testing facility.\n2. Failure to establish procedures for a system for the handling of the test and control articles to ensure that (1) proper identification is maintained throughout the distribution process and (2) the receipt and distribution of each batch is documented. Such documentation shall include the date and quantity of each batch distributed or returned [21 CFR 58.107(c) and (d)].\nYour failures to adhere to this requirement include, but are not limited to, the following examples:\na. Verification of the lot\u002Fbatch number was not found to be documented during sample receipt, preparation, or on any other source data records.\nb. Your firm’s Sample Information Form - (b)(4)052 listed the sample quantity received for study (b)(4) (Safety Intravenous Needles for Single Use) as “3 packs” with no record of how many needles were in each pack. The form then lists 1 and ¼ of a pack were distributed on (b)(4), and (b)(4), respectively. The same amounts were then listed as returned on (b)(4), and (b)(4), respectively. The form goes on to list that \"3 packs\" were disposed of on (b)(4). There was no record of the number of needles used and returned.\nc. Your firm’s sample preparation form (b)(4)83 does not require verification or documentation of the lot number or quantity of needles used for extraction for GPMT testing.\nd. The investigators found 12 GLP studies (refer to table below) where, after completion of the testing, the study director made changes to the test article information (indicated in bold in the table) or updated the test article photo (indicated by [1] in the table) in the final study report at the sponsor's request. These changes included revisions to the test article lot #, material, and size information, suggesting that proper identification is not maintained throughout the distribution process.\nStudy\nNumber: \"SSMT-S\"Test article per protocol:Studies\nCompleted:Change\nRequest date:Test article per final study report:\n(b)(4)(b)(4)(b)(4)(b)(4)(b)(4)\n\n1 The photo of the test article in the final report is not the same as the one in the protocol.\nFailure to have established procedures for the handling of the test and control articles to ensure that proper identification of the articles is maintained and that the receipt and distribution of each batch are documented as required by the regulations creates the potential for errors to occur during handling such that the incorrect information could be attributed to the article under study. This in turn could lead to testing discrepancies and inaccurate test results and conclusions. In addition, lack of these procedures adversely impacts the traceability of the test samples, reliability of the testing, and the manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials, as applicable.\nYour written response is inadequate. The written response you provided states that the relevant standard operating procedures (SOPs) addressing the concerns noted in the Form 483 will be revised, and GLP experts will be invited to provide training on FDA GLP and 510(k) regulations.\nHowever, your response did not: (1) include copies of revised SOPs (b)(4)-002 and (b)(4)-003 and (2) provide details regarding the proposed trainings, including information on the types of personnel that will undergo the trainings, training materials that will be used, and how the effectiveness of the training will be evaluated. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide assurance that these violations will not occur again.\n3. Failure of the Quality Assurance Unit (QAU) to inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection and to bring any problems found during the course of an inspection which are likely to affect study integrity to the attention of the study director and management immediately [21 CFR 58.35(b)(3)].\nGLP regulations require that QAU inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection showing the date of the inspection, the study inspected, the phase or segment of the study inspected, the person performing the inspection, findings and problems, action recommended and taken to resolve existing problems, and any scheduled date for reinspection. Any problems found during the course of an inspection which are likely to affect study integrity shall be brought to the attention of the study director and management immediately. Examples of the QAU’s failures include, but are not limited to, the following:\na. The QAU failed to identify any of the data irregularities, errors, and omissions that were observed by FDA, including those described in the examples of failures throughout this letter.\nb. There were 67 studies reviewed during the inspection, of which 63 were conducted from 2023-2024. For these 63 studies, the final study reports include a signature attesting that the QAU audited the protocol, raw data, and final study reports. However, records did not support that all reported audits were completed at the reported times. Examples are as follows:\n1. Only three ((b)(4)) out of the 63 covered studies had record of a raw data audit per the QA inspection summary reports.\n2. Thirty out of the 63 covered studies did not have the reported final study report audits included on the QA inspection summary reports.\n3. Study (b)(4), completed on (b)(4), was observed to have an error within the printed cassette labels; however, there was no deviation or record of when this error was discovered or that it had been reported to the study director. The FDA investigators found the final report for this study was still in draft form but included the quality assurance statement reporting QAU inspections of the study protocol on (b)(4), and the raw data and final study report on (b)(4). However, when asked to provide copies of those QA audit reports, your firm only provided a copy of a QAU inspection report for the study protocol which was dated (b)(4). This audit report was not recorded on the QA Summary Report of Inspections. These discrepancies, including differences between the protocol audit date recorded in the quality assurance statement of the draft study report versus in the QAU inspection report, along with the missing audit report for the final study report and raw data, and lack of related audits mentioned in the QA Summary Report of Inspections, indicate a lack of adequate monitoring by the QAU.\nA reliable QAU is integral to the successful understanding and completion of any GLP study. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report are accurate and valid. Failure to perform QAU functions, such as monitoring studies to ensure protocols were followed and data are accurately recorded, over the course of multiple studies also calls into question the quality and integrity of studies conducted at your testing facility.\nYour written response is inadequate. Your written response included a document that outlines your QAU’s review of QA statements, corresponding QA inspection reports, and Summary of Inspection Report for the final study reports reviewed by the FDA investigators. You also indicated in your response that the relevant SOPs addressing the concerns noted in the Form 483 will be revised along with Form QAU-F002 “Summary of Inspection Report”, interviews will be conducted with QA personnel to clarify responsibilities, a gap analysis of the existing quality management system will be conducted, and a working group will be established to identify existing problems and make improvements. Additionally, you stated plans to have training provided by an external GLP expert. However, your response did not: (1) include copies of the revised SOPs and form such that the adequacy of the revisions can be assessed and (2) provide details regarding the proposed trainings, including the training materials that will be used and how the effectiveness of the training will be evaluated. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide reasonable assurance that QAU failures will be avoided in the future.\n4. Failure of a testing facility to have standard operating procedures in writing setting forth nonclinical laboratory study methods that management is satisfied are adequate to ensure the quality and integrity of the data generated in the course of a study. The study director failed to authorize all deviations in the study from standard operating procedures and ensure the deviations were documented in the raw data [21 CFR 58.81(a)].\nSOPs should be adequate to ensure the quality and integrity of data generated in a study. However, not all SOPs appear to be adequate. The study director also must authorize all deviations from SOPs in a study and document all study deviations in the raw data. However, the study directors at your testing facility did not adhere to these requirements. Deviations from standard operating procedures in a study also were not authorized by the study director and documented in the raw data. Examples of these issues include the following:\na. Your firm was found to be operating under two sets of SOPs for conducting the same types of tests. One was originated for conducting testing per domestic standards and the more recent set is referred to as your GLP SOPs. There were no instructions directing which SOPs were to be used for any given study. FDA investigators found conflicting instructions between your firm’s \"domestic\" study procedures and your \"GLP\" procedures. For example, the domestic SOP, SOP-(b)(4)02 Animal Clinical Observation requires the use of four separate forms ((b)(4): General clinical observation during study, (b)(4): Detailed clinical observation during study, (b)(4): General clinical observation during quarantine, and (b)(4): Detailed clinical observation during quarantine) to record clinical observations separately while animals are in quarantine versus on study. However, the corresponding GLP SOP (b)(4)-028 only requires one form to document clinical observations while animals are in quarantine ((b)(4): Animal Reception, Animal Receipt, Distribution and Quarantine Records) and does not have any requirement to use certain forms for documenting observations while on study. The lack of appropriate forms to document observations in your “GLP” procedures indicates the inadequacy of your SOPs to ensure the quality and integrity of data generated. Additionally, the GLP SOP states that, “The study personnel should fill out the animal observation records in the corresponding experimental records daily.” However, as described under violation 1 of this letter, it does not appear that daily animal observations were being recorded in accordance with this SOP. This deviation from the SOP does not appear to be authorized by the study directors nor documented in the raw data.\nb. SOP (b)(4)-028: “Animal clinical observation and management of abnormal conditions” does not include any information on signs of abnormal conditions based on species, though GLP studies were conducted on mice, rats, and rabbits. Lack of sufficient detail within this SOP could lead to errors in identifying abnormal conditions exhibited by study animals which in turn could directly impact the quality and integrity of the data generated in the course of the studies.\nc. SOP (b)(4)-030: “Skin Sensitization Test (Guinea Pig Maximization Test)” does not include adequate instructions for clinical observation of the animals during the studies, such as assuring that their breathing is not restricted when wrapping them with the occlusive dressings during the challenge and induction phases and that animals undergo observation daily to ensure isolation and treatment of any wounds or illness throughout the study. Additionally, the SOP and training materials for the GPMT test lacked photos to demonstrate how to use the Magnusson Kligman scores. Clinical observations are essential to the quality and integrity of the data generated from this testing, and this SOP was found to lack sufficient detail to ensure that tests can be conducted reliably and consistently.\nFailure of a testing facility to have adequate SOPs, or follow established SOPs if adequate, in multiple studies with multiple study directors over many months suggests systemic failures in the operation of your nonclinical laboratory. This failure raises questions about the reliability and accuracy of the data and does not ensure the quality and integrity of data generated in a study. Failing to follow SOPs and having inadequate SOPs yield inadequate protocols that introduce ambiguity and uncertainty as to how study requirements are to be followed, as well as inconsistent execution of studies and unreliable study results. Any deviations from the SOPs must be authorized by the study director and documented in the raw data. Failure to properly document any authorized deviations could result in study data with a high level of variability that challenges the ability to effectively interpret the study results associated with a device. This in turn adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials, if applicable.\nYour written response is inadequate. Your written response acknowledged the observations cited and indicated that the relevant SOPs addressing the concerns noted in the Form 483 will be revised, a gap analysis of the existing quality management system will be conducted, and an external GLP expert will be engaged to perform an audit. However, the response did not: (1) include copies of the revised SOPs such that the adequacy of the revisions can be assessed (2) describe plans for retraining personnel on revised SOPs (3) detail how your testing facility will ensure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; (4) address any planned preventive actions such as frequency (i.e., quarterly, annual) of audits to check for compliance or future training of new study directors, as applicable; and (5) detail how appropriate documentation\u002Ffollow-up will be ensured when deviations arise in the future. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your written response does not provide assurance that similar violations would not occur again.\n5. Failure of the testing facility to ensure that all newly received animals from outside sources were isolated and their health status evaluated in accordance with acceptable veterinary medical practice [21 CFR 58.90(b)].\nAll newly received animals should be isolated and evaluated to determine health status. This can allow for early detection of potential health issues. Your failures to adhere to this requirement include, but are not limited to, the following examples:\na. The FDA investigators reviewed guinea pig receiving and quarantine records totaling five months during 2023 and 2024. The records documented that the firm received over (b)(4) guinea pigs in these five months and all these guinea pigs were recorded as \"normal\" or \"okay\" with no deaths reported while in quarantine. This seems highly implausible as there were six deaths among 903 animals in the guinea pig quarantine room (b)(4) over a two-day period that occurred during the inspection.\nb. Your firm’s records indicate on at least one occasion while still conducting GLP rabbit studies, you received more rabbits than you have the capacity to isolate for the required time. For example, 180 New Zealand White Rabbits were received on (b)(4), and these rabbits were reportedly held under quarantine from (b)(4). However, according to your firm, the capacity across all designated rabbit quarantine rooms in your (b)(4) building ((b)(4) in the (b)(4) building) is 141 rabbits.\nYour records raise significant concerns regarding your isolation procedures as well as your evaluation of the status of test animals. Failure to isolate newly received animals or evaluate the animal’s health status can raise serious concerns about the validity of study data. Animals may be sick upon arrival. If transferred to housing with other test animals already enrolled in another study, the newly received test animal could make the other test animals sick and impact study results. Further, test animals must be free of any disease or condition that might interfere at the beginning of a study or may significantly impact study data and\u002For results.\nYour firm’s failure to have adequate intake and isolation procedures for test animals arriving at your facility suggests systemic failures in your firm’s nonclinical laboratory practices. Further, failures that relate to test animals used in numerous studies raises questions about the quality and integrity of data collected at your facility.\nYour written response is inadequate. Your written response includes revising SOP (b)(4)-002, issuing death reports for the six guinea pig deaths identified during the inspection, and converting Room (b)(4) in Building (b)(4) into a rabbit quarantine room, adding (b)(4) cages to comply with company standards. However, your response does not include: (1) copies of the revised SOP such that the adequacy of the revisions can be assessed, (2) documentation that addresses the changes to the rabbit quarantine room by adding additional cages to accommodate the animals more efficiently, and (3) documentation that demonstrates the special training for QAU personnel on SOP (b)(4)-002 procedures was conducted and Quality Assurance Manager roles and responsibilities have been established. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Your explanation, when taken into consideration with the violations described above, which occurred over many months, suggests systemic failure in study director and veterinarian oversight of nonclinical laboratory studies and brings into question data integrity and animal care and welfare at your testing facility.\n6. Failure of the testing facility to ensure warm-blooded animals, excluding suckling rodents, used in laboratory procedures that require manipulations and observations over an extended period of time or in studies that require the animals to be removed from and returned to their home cages for any reason (e.g., cage cleaning, treatment, etc.) received appropriate identification [21 CFR 58.90(d)].\nYour failures to adhere to this requirement include, but are not limited to, the following example:\na. Your firm does not use unique or study-specific animal identification numbers to prevent mix-ups during studies that require animals be removed from their cages for study related procedures including weighing and assessments. For example, for 11 GPMT studies started on (b)(4), and completed (b)(4), and 14 GPMT studies started on (b)(4), and completed (b)(4), the polar negative control group animals for each study are all identified as “(b)(4)” to “(b)(4)” and the non-polar vehicle controls are “(b)(4)” to “(b)(4).” All the test animals for each study are numbered “(b)(4)” to “(b)(4)” for the polar and “(b)(4)” to “(b)(4)” for the non-polar. The records the FDA investigators reviewed indicated your firm has assessed and weighed guinea pigs with identical IDs from multiple studies concurrently, in the same room, and on the same scale.\nFailure to appropriately identify each animal by ensuring that they are identified with unique, study-specific identification numbers raises concerns about lack of traceability of the specific animal in the cage to the test and\u002For to the results of the testing presented in the reports. The inability to distinguish the test animals and control animals across different studies raises serious concerns about the validity of the test results. Since the ability to identify specific animals is foundational to being able to draw scientifically valid conclusions from the studies, the accuracy of study results cannot be verified.\nYour written response does not adequately address the issue of misidentification. Your written response includes revising the SOP ((b)(4)-002) to enforce unique animal identification numbers. It also includes revising test records for guinea pig studies to add unique ID numbers to ensure data traceability and the recruitment of external GLP experts to train staff on FDA 21 CFR Part 58. However, your response does not include copies of the revised SOP such that the adequacy of the revisions can be assessed, written documentation of the GLP training information, nor does it discuss the specific personnel that will undergo the future GLP training and\u002For newly implemented procedures as applicable. Given the deviations and issues cited in the violations above, it is necessary to review the training materials to determine their adequacy for the trained individuals to both conduct the tests per the standards being used, and to produce accurate, traceable results. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your written response does not provide assurance that misidentification of animals would not reoccur.\n7. Failure to provide a separate laboratory space, as needed, for the performance of the routine and specialized procedures required by nonclinical laboratory studies [21 CFR 58.49].\nA testing facility must provide separate laboratory space for routine and specialized procedures required by nonclinical laboratory studies, as needed. This requirement ensures that studies are conducted in a controlled environment and that potentially hazardous materials or procedures are isolated from other operations. Your failures to adhere to this requirement include, but are not limited to, the following examples:\na. According to your firm’s floor plan for Building (b)(4), rooms (b)(4) and (b)(4) are listed as a “Procedure Room” and “Anteroom” respectively, with (b)(4) connecting to Guinea Pig Room (b)(4), and (b)(4) connecting to Guinea Pig Room (b)(4). During the inspection, study director (b)(6) indicated that Rooms (b)(4) and (b)(4) are shared as the procedure rooms for both rabbits and guinea pigs for rabbit intracutaneous reactivity studies and for guinea pig sensitization studies, respectively. Not only are they shared space for different species, according to your firm’s floor plan, these two rooms are connected, not separate. Maintaining proper separation of species or test systems is a requirement per 21 CFR 58.43(a)(1).\nb. During the inspection, it was found that scale (b)(4)-494 located in one of the rabbit pyrogen rooms, is shared for measuring weights of both rabbits and guinea pig species. It was also found that your firm does not have procedures for cleaning the room or equipment between studies of different species, as required per 21 CFR 58.81(b)(11).\nc. There is inadequate space in both rabbit pyrogen test rooms (b)(4) and (b)(4) to conduct the procedures that are required for this test. Per the United States Pharmacopeia (USP) \u003C151> Pyrogenicity Test standard for the rabbit pyrogen test, it should be conducted in a separate area designated solely for pyrogen testing and under environmental conditions that are free from disturbances likely to excite the rabbits. According to study director (b)(6), due to the limited space in the rooms, rabbits are transferred one at a time from the rabbit feeding rooms and put on the restrainers. This opening and closing the doors causes repeated disturbances to the rabbits already transferred to the pyrogen room as they await testing. In addition, there is extremely limited space for personnel to move around or to conduct procedures on the rabbits without disturbing the others.\nSeparation of animal species during biomedical testing is important to prevent interspecies disease transmission, minimize potential anxiety and behavioral changes due to conflict, and ensure the reliability of experimental results. The presence of multiple intermixed species can introduce confounding factors into in vivo testing, making it difficult to isolate the effects of a specific treatment or intervention, which impacts data integrity. Minimizing additional stress in terms of designating adequate laboratory space for procedures and housing is also important for the health and welfare of the study animals.\nYour written response is inadequate. Your written response included an explanation of the planned corrections, including: (1) dedicating rooms (b)(4) to performing guinea pig studies only, (2) reducing the number of rabbit pyrogen tests in rooms (b)(4) and (b)(4) to ensure the number of test items matches the facility’s capacity, (3) transferring of some pyrogen testing to the backup laboratory to comply with USP \u003C151>, and (4) revising SOPs (b)(4)-014 and (b)(4)-002.\nHowever, the response did not provide the following: (1) objective evidence that the appropriate SOPs have been revised, and (2) documentation that addresses the changes to the designation of different testing rooms to accommodate the animals more efficiently. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. In addition, your response stated that priority was given to completing a volume of studies over GLP compliance, which resulted in insufficient space to assure proper adherence to regulatory requirements. This suggests that these issues are systemic and brings into question the quality and integrity of the laboratory operation areas and data collected at your testing facility. Therefore, your response does not provide assurance that these violations will not occur again.\n8. Failure of the Quality Assurance Unit (QAU) to maintain a copy of a master schedule sheet of all nonclinical laboratory studies conducted at the testing facility indexed by test article and containing the test system, nature of study, date study was initiated, current status of each study, identity of the sponsor, and name of the study director [21 CFR 58.35(b)(1)].\nYour failures to adhere to this requirement include, but are not limited, to the following examples:\na. There was no master schedule (MS) prior to February 12, 2022, but your firm has been conducting GLP studies since at least April 2020. Moreover, the MS does not include the sponsor or test system.\nb. Per your SOP (b)(4)-014, the test facility manager is responsible for maintaining the master schedule, not the QAU.\nc. In addition, the FDA investigators found the following completed GLP studies were archived but were not included on the master schedule: (b)(4).\nWithout a complete and accurate MS, the study director and QAU would not know which studies are underway, at which stages and when inspections or audits are indicated. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report are accurate and valid. Failure to perform QAU functions can have a negative impact on a study because it indicates a lack of oversight to ensure compliance with all applicable GLP regulations and calls into question the quality and integrity of studies conducted.\nYour written response is inadequate. Your written response attributes these failures to inadequate planning and insufficient training to ensure that GLP requirements are fully understood. You propose to correct the MS to include all GLP studies conducted from (b)(4) to present. Your corrective action includes revising “SOP (b)(4)-013 Project Acceptance, Distribution of Project Numbers, Assignment of Project Leaders, and Management of Master Plan Forms,” among other actions. However, it does not provide documentation that the appropriate SOPs have been revised. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide assurances that QAU failures will be avoided in the future.\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your facility. It is your responsibility as a non-clinical laboratory to ensure compliance with the Act and applicable regulations.\nFDA acknowledges that your written response dated February 21, 2025, included a signed letter stating that “…due to the increasingly intense price competition within the domestic market, our institution has become unsustainable to support the basic costs associated with full system compliance. This presents significant long-term challenges and risks to our institution, as well as potential product quality risks for our customers. As a result, we hereby affirm that, effective immediately, we will suspend all FDA-related non-clinical testing for a minimum period of three years, until December 31, 2027.” Furthermore, you state that, “In the event that our company decides to resume FDA-related non-clinical testing services after January 1, 2028, we commit to the following:\nSubmitting a formal notification to the FDA at least six (6) months prior to any planned resumption of services, detailing our operational readiness and compliance measures.\nResuming services only after obtaining written authorization from the FDA and ensuring alignment with current regulatory expectations.\nEnsuring that all activities are conducted in full compliance with the FDA’s most recent regulatory requirements, quality standards, and inspection protocols in effect at the time of resumption.”\nWithin 15 working days of receiving this letter, please provide documentation of the additional corrective and preventive actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the testing facility. Any submitted corrective action plan should include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. In addition, please provide a complete list of all nonclinical laboratory studies of FDA-regulated devices for the last five years, including the name of the study, the test article, the name of the study director and sponsor, and the current status of the study. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you. In addition, FDA could initiate disqualification proceedings against you in accordance with 21 CFR 58.202. If you believe that you have complied with the FD&C Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\nYour response should reference “CTS# EC250079\u002FE001” and be sent via email to: Irfan.Khan@fda.hhs.gov.\nA copy of this letter has been sent to FDA’s OBMI Foreign Inspection Cadre via email FDAInternationalBIMO@fda.hhs.gov. Please send a copy of your response to that office.\nIf you have any questions, please contact Angela Dixon-Allamby, by phone at (301) 796-5548 or email at Angela.Dixon-Allamby@fda.hhs.gov.\nSincerely yours,\n\u002FS\u002F\nSoma Kalb, PhD\nDirector\nDCEA1: Division of Clinical Policy and Quality\nOffice of Clinical Evidence & Analysis\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Jiangsu Kerbio Medical Technology Group Co.","jiangsu-kerbio-medical-technology-group-co-705188-07112025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-kerbio-medical-technology-group-co-705188-07112025","2026-10-26T08:09:04.055844+00:00","2025-08-26","705188","Mr. Shangyou Lin","2026-08-19T16:28:49.942+00:00","2025-07-11",{"id":174,"raw":175,"subject":178,"body_html":179,"body_text":180,"firm_name":181,"letter_id":182,"created_at":144,"fei_number":19,"letter_url":183,"updated_at":184,"action_type":22,"case_status":23,"posted_date":147,"marcs_cms_no":185,"product_type":110,"closeout_date":19,"issuing_office":11,"recipient_name":186,"body_fetched_at":187,"delivery_method":151,"recipient_title":19,"reference_number":188,"action_taken_date":189,"medical_device_id":19,"response_letter_date":19},22198,[136,176,177,11,178,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026\">Nanjing Hanxin Pharmaceutical Technology Co. Ltd.\u003C\u002Fa>","Request for Records\u002FCGMP\u002FAPI\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-19\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Bob Bao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nanjing Hanxin Pharmaceutical Technology Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Building C5, No. 9, Weidi Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Xianlin University Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nanjing Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>, \u003Cspan>210046\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 3, 2026\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-19\u003C\u002Fp>\u003Cp>To Mr. Bob Bao:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant deviations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you the opportunity to address them. Promptly address any deviations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the deviations in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any deviations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Deviations were documented during review of your drug manufacturing facility, Nanjing Hanxin Pharmaceutical Technology Co. Ltd., FDA Establishment Identifier (FEI) 3015142388. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility was registered with the United States FDA as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our November 18, 2025 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs.\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>The following deviations were identified during our review. As a reminder, this is not an all-inclusive list of deviations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure of your quality unit to exercise its responsibility to ensure the APIs manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a manufacturer of \u003Cstrong>(b)(4)\u003C\u002Fstrong> APIs, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> APIs. These APIs are for use in further processing to produce sterile drug products and for pharmaceutical compounding operations. Based on the records and information you provided, your quality unit (QU) failed to adequately qualify your suppliers of critical raw materials for the manufacturing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> API at your facility.\u003C\u002Fp>\u003Cp>Your firm was \u003Cstrong>(b)(4)\u003C\u002Fstrong> based upon an acceptable FDA inspection. Since then, your firm \u003Cstrong>(b)(4)\u003C\u002Fstrong> API. However, in your response to our records request for quality information on drugs you produced, you did not provide any documentation with regard to the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> API at your facility. FDA sent a subsequent request for additional information, regarding \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing operations at your facility. Your response indicated that after November 2025, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> production was moved to a subsidiary of your company, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your firm qualified \u003Cstrong>(b)(4)\u003C\u002Fstrong> as your supplier for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a critical starting material to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> API for U.S. distribution. FDA conducted an inspection in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and concluded the drugs manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong> are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), because of their methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP. Drugs manufactured at \u003Cstrong>(b)(4)\u003C\u002Fstrong> were placed on IA 66-40. See FDA Warning Letter \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> issued to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for further details.\u003C\u002Fp>\u003Cp>Your oversight of your suppliers is deficient. FDA is also concerned that identifying your firm and not the actual manufacturer of \u003Cstrong>(b)(4)\u003C\u002Fstrong> API may have been an attempt to circumvent safeguards associated with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and may pose a risk to consumers of receiving substandard \u003Cstrong>(b)(4)\u003C\u002Fstrong> APIs.\u003C\u002Fp>\u003Cp>For manufacturers whose drugs are placed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alerts appear to be adulterated. You are responsible for ensuring that the drugs you receive and distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding the import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A summary of your systemic corrective action and preventive action (CAPA) plan to remediate the supplier qualification program and prevent use of unsuitable material suppliers.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each lot and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>Your stability report and data to support the claimed retest date for all of your APIs intended for U.S. market.\u003C\u002Fli>\u003Cli>A list of all drugs you distributed in the last three years, and the name of the original supplier\u002Fmanufacturer, or supplier of starting material, such as crude API.\u003C\u002Fli>\u003Cli>For any lots of APIs identified as being produced from materials from a non-compliant supplier\u002Fmanufacturer, notify your customers in writing, and provide copies of these notifications in response to this letter. Include lot identification and recommended actions in your notifications.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Importation of Unapproved Drugs -\u003C\u002Fstrong> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your facility lists various APIs under its manufacturer registration that were not referenced in your response to the 704(a)(4) records request but were active under your registration at the time the request was issued, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please be advised that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not an API permissible for use in human drug compounding under sections 503A or 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the causes of any deviations and implementing corrective and preventative measures to ensure future and sustained compliance so that these deviations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on June 22, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Nanjing Hanxin Pharmaceutical Technology Co. Ltd., located at Building C5, No. 9, Weidi Road, Xianlin University Town, Nanjing, Jiangsu into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015142388 and ATTN: Compliance officer Joan Johnson in the subject line of the email. If you have information that you believe demonstrates that your drugs do not deviate from the FD&amp;C Act, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA post warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-19\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Bob Bao\n\nRecipient Title\n\nGeneral Manager\n\nNanjing Hanxin Pharmaceutical Technology Co. Ltd.\n\nBuilding C5, No. 9, Weidi Road\n\nXianlin University Town\n\nNanjing Shi\n\nJiangsu Sheng, 210046\n\nChina\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nNovember 3, 2026\nWARNING LETTER\nReference number: 320-27-19\nTo Mr. Bob Bao:\nThis warning letter advises you of significant deviations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you the opportunity to address them. Promptly address any deviations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the deviations in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any deviations may result in regulatory action without further notice.\nFDA Review\nDeviations were documented during review of your drug manufacturing facility, Nanjing Hanxin Pharmaceutical Technology Co. Ltd., FDA Establishment Identifier (FEI) 3015142388. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility was registered with the United States FDA as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our November 18, 2025 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs.\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThe following deviations were identified during our review. As a reminder, this is not an all-inclusive list of deviations at your facility.\nFailure of your quality unit to exercise its responsibility to ensure the APIs manufactured at your facility are in compliance with CGMP.\nYour firm is a manufacturer of (b)(4) APIs, including (b)(4) APIs. These APIs are for use in further processing to produce sterile drug products and for pharmaceutical compounding operations. Based on the records and information you provided, your quality unit (QU) failed to adequately qualify your suppliers of critical raw materials for the manufacturing of (b)(4) API at your facility.\nYour firm was (b)(4) based upon an acceptable FDA inspection. Since then, your firm (b)(4) API. However, in your response to our records request for quality information on drugs you produced, you did not provide any documentation with regard to the manufacture of (b)(4) API at your facility. FDA sent a subsequent request for additional information, regarding (b)(4) manufacturing operations at your facility. Your response indicated that after November 2025, the (b)(4) production was moved to a subsidiary of your company, (b)(4).\nYour firm qualified (b)(4) as your supplier for (b)(4), a critical starting material to manufacture (b)(4) API for U.S. distribution. FDA conducted an inspection in (b)(4) and concluded the drugs manufactured by (b)(4) are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), because of their methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP. Drugs manufactured at (b)(4) were placed on IA 66-40. See FDA Warning Letter (b)(4)1 issued to (b)(4) for further details.\nYour oversight of your suppliers is deficient. FDA is also concerned that identifying your firm and not the actual manufacturer of (b)(4) API may have been an attempt to circumvent safeguards associated with the (b)(4) and may pose a risk to consumers of receiving substandard (b)(4) APIs.\nFor manufacturers whose drugs are placed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alerts appear to be adulterated. You are responsible for ensuring that the drugs you receive and distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding the import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nIn response to this letter, provide:\nA summary of your systemic corrective action and preventive action (CAPA) plan to remediate the supplier qualification program and prevent use of unsuitable material suppliers.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each lot and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nYour stability report and data to support the claimed retest date for all of your APIs intended for U.S. market.\nA list of all drugs you distributed in the last three years, and the name of the original supplier\u002Fmanufacturer, or supplier of starting material, such as crude API.\nFor any lots of APIs identified as being produced from materials from a non-compliant supplier\u002Fmanufacturer, notify your customers in writing, and provide copies of these notifications in response to this letter. Include lot identification and recommended actions in your notifications.\nImportation of Unapproved Drugs - (b)(4)\nYour facility lists various APIs under its manufacturer registration that were not referenced in your response to the 704(a)(4) records request but were active under your registration at the time the request was issued, including (b)(4). Please be advised that (b)(4) is not an API permissible for use in human drug compounding under sections 503A or 503B of the FD&C Act.\nConclusion\nAs previously stated, you are responsible for investigating and determining the causes of any deviations and implementing corrective and preventative measures to ensure future and sustained compliance so that these deviations and any others do not occur.\nFDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on June 22, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Nanjing Hanxin Pharmaceutical Technology Co. Ltd., located at Building C5, No. 9, Weidi Road, Xianlin University Town, Nanjing, Jiangsu into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015142388 and ATTN: Compliance officer Joan Johnson in the subject line of the email. If you have information that you believe demonstrates that your drugs do not deviate from the FD&C Act, include that information for our consideration.\nFDA post warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_____________________\n1 (b)(4)","Nanjing Hanxin Pharmaceutical Technology Co. Ltd.","nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026","2026-11-17T01:02:34.878331+00:00","734913","Mr. Bob Bao","2026-11-17T01:02:34.679+00:00","320-27-19","2026-11-03",{"id":191,"raw":192,"subject":197,"body_html":198,"body_text":199,"firm_name":200,"letter_id":201,"created_at":202,"fei_number":19,"letter_url":203,"updated_at":204,"action_type":22,"case_status":23,"posted_date":205,"marcs_cms_no":206,"product_type":110,"closeout_date":19,"issuing_office":196,"recipient_name":207,"body_fetched_at":208,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":209,"medical_device_id":19,"response_letter_date":19},2953,[193,194,195,196,197,13,13,13],"\u003Ctime datetime=\"2021-12-21T14:20:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-14T05:00:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangdong-kemei-pharmaceutical-technology-co-ltd-612090-12142021\">Guangdong Kemei Pharmaceutical Technology Co. Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jack Chen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Guangdong Kemei Pharmaceutical Technology Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2,4, No.16 (#6 Plant), Jiye Road, 3rd &amp; 4th Floor\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Songgang Songxia Industrial Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shishan Foshan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>528225\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-22-07\u003C\u002Fp>\n\n\u003Cp>December 14, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chen:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as IMC WASH-FREE HAND SANITIZER. This drug product was declared to be manufactured at your facility, Guangdong Kemei Pharmaceutical Technology Co. Ltd, FEI 3017086967, at 2,4, No.16 (#6 Plant), Jiye Road 3rd &amp; 4th Floor, Songgang Songxia Industrial Park, Shishan Foshan, China. Following an attempt to import IMC WASH-FREE HAND SANITIZER into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, IMC WASH-FREE HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (x) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (x) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>IMC WASH-FREE HAND SANITIZER, declared to be manufactured at your facility, is labeled to contain 75% of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average 35% ethanol volume\u002Fvolume (v\u002Fv) and an average of 32% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>On December 15, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug products at the following webpage: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>After several unsuccessful attempts to contact you, FDA contacted your firm’s consignees to discuss marketed action.\u003C\u002Fp>\n\n\u003Cp>On December 23, 2020, one of your firm’s consignees, Shane Erickson Inc., recalled one lot of Wash-Free Hand Sanitizer (50ml, 100ml and 300ml size bottles) and one lot of Thrifty White Pharmacy Wash-Free Hand Sanitizer due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website: shane-erickson-inc-dba-innovative-marketing-consultants-issues-voluntary-nationwide-recall-wash-free\u003C\u002Fp>\n\n\u003Cp>On January 14-15, 2021, FDA received correspondence from your firm stating you were not the manufacturer of IMC brand products and that you had given your “FDA certificates” to this third-party that likely manufactured the contaminated hand sanitizer products.\u003C\u002Fp>\n\n\u003Cp>On January 25, 2021, FDA held a teleconference with your firm. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market that were labeled as or declared as manufactured by your firm, Guangdong Kemei Pharmaceutical Technology Co. Ltd. Your firm agreed to support the recall of IMC hand sanitizer products. However, to date, your firm has not committed to recall.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation into how the drug product described above, which was declared to be manufactured at your facility and which was labeled as containing ethanol, was substituted in part or in whole with methanol.\u003C\u002Fli>\n\t\u003Cli>A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003C\u002Fli>\n\t\u003Cli>A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fli>\n\t\u003Cli>Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The substitution and contamination with methanol in a drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>IMC WASH-FREE HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), and because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic. Examples of claims observed on the IMC WASH-FREE HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“WASH-FREE HAND SANITIZER… Drug Facts…Purpose…Antiseptic…Use(s) to help reduce bacteria on skin…Directions…Apply a small amount in you palm and rub hands together briskly until dry…”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your IMC WASH-FREE HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety and effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, IMC WASH-FREE HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, IMC WASH-FREE HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 75% v\u002Fv. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that IMC WASH-FREE HAND SANITIZER contains ethanol in a concentration that is less than the 75% v\u002Fv stated on its product label and less than the amount of ethanol described in the 1994 TFM. Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidance setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses also demonstrated that batches of IMC WASH-FREE HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, IMC WASH-FREE HAND SANITIZER, is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (x), and (ee).\u003C\u002Fp>\n\n\u003Cp>It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, IMC WASH-FREE HAND SANITIZER is labeled to contain ethyl alcohol 75% v\u002Fv. However, FDA laboratory analysis of batches of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of this product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>IMC WASH-FREE HAND SANITIZER is also misbranded under section 502(x) of the FD&amp;C Act, 21 U.S.C. 352(x) because the product label fails to disclose a complete domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because IMC WASH-FREE HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features a statement of identity of the commodity.” Under section 505G(a)(3) of the FD&amp;C Act and the 1994 TFM, the statement of identity for health-care antiseptic drug products, a category that included consumer antiseptic rub drug products, must contain “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel. However, we recommend that you include the name “alcohol gel” as part of the statement of identity that appears on the principal display panel of the label for IMC WASH-FREE HAND SANITIZER which will allow consumers to make an informed decisions regarding your topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on January 7, 2021, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3017086967 and ATTN: LaKeesha Foster Sifontes.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nRegistered US Agent\u003Cbr>\nVizocom ICT LLC\u003Cbr>\n860 Jamacha Rd. Ste. 104\u003Cbr>\nEl Cajon, CA 92019\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products manufactured at your facility, a review of the purported formulations on the drug product’s labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jack Chen\n\nRecipient Title\n\nCEO\n\nGuangdong Kemei Pharmaceutical Technology Co. Ltd.\n\n2,4, No.16 (#6 Plant), Jiye Road, 3rd & 4th Floor\n\nSonggang Songxia Industrial Park\n\nShishan Foshan\n\n528225\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-22-07\n\nDecember 14, 2021\n\nDear Mr. Chen:\n\nYour firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as IMC WASH-FREE HAND SANITIZER. This drug product was declared to be manufactured at your facility, Guangdong Kemei Pharmaceutical Technology Co. Ltd, FEI 3017086967, at 2,4, No.16 (#6 Plant), Jiye Road 3rd & 4th Floor, Songgang Songxia Industrial Park, Shishan Foshan, China. Following an attempt to import IMC WASH-FREE HAND SANITIZER into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, IMC WASH-FREE HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (x) and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (x) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nIMC WASH-FREE HAND SANITIZER, declared to be manufactured at your facility, is labeled to contain 75% of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average 35% ethanol volume\u002Fvolume (v\u002Fv) and an average of 32% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nOn December 15, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug products at the following webpage: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nAfter several unsuccessful attempts to contact you, FDA contacted your firm’s consignees to discuss marketed action.\n\nOn December 23, 2020, one of your firm’s consignees, Shane Erickson Inc., recalled one lot of Wash-Free Hand Sanitizer (50ml, 100ml and 300ml size bottles) and one lot of Thrifty White Pharmacy Wash-Free Hand Sanitizer due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website: shane-erickson-inc-dba-innovative-marketing-consultants-issues-voluntary-nationwide-recall-wash-free\n\nOn January 14-15, 2021, FDA received correspondence from your firm stating you were not the manufacturer of IMC brand products and that you had given your “FDA certificates” to this third-party that likely manufactured the contaminated hand sanitizer products.\n\nOn January 25, 2021, FDA held a teleconference with your firm. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market that were labeled as or declared as manufactured by your firm, Guangdong Kemei Pharmaceutical Technology Co. Ltd. Your firm agreed to support the recall of IMC hand sanitizer products. However, to date, your firm has not committed to recall.\n\nIn response to this letter, provide the following:\n\nA detailed investigation into how the drug product described above, which was declared to be manufactured at your facility and which was labeled as containing ethanol, was substituted in part or in whole with methanol.\n\nA list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\nA list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\nCopies of the complete batch records for all batches distributed to the U.S.\n\nThe substitution and contamination with methanol in a drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.1\n\nUnapproved New Drug and Misbranding Violations\n\nIMC WASH-FREE HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), and because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic. Examples of claims observed on the IMC WASH-FREE HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“WASH-FREE HAND SANITIZER… Drug Facts…Purpose…Antiseptic…Use(s) to help reduce bacteria on skin…Directions…Apply a small amount in you palm and rub hands together briskly until dry…”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your IMC WASH-FREE HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety and effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, IMC WASH-FREE HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, IMC WASH-FREE HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 75% v\u002Fv. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that IMC WASH-FREE HAND SANITIZER contains ethanol in a concentration that is less than the 75% v\u002Fv stated on its product label and less than the amount of ethanol described in the 1994 TFM. Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidance setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\n\nFDA laboratory analyses also demonstrated that batches of IMC WASH-FREE HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\n\nAdditionally, this methanol-containing drug product, IMC WASH-FREE HAND SANITIZER, is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (x), and (ee).\n\nIt is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, IMC WASH-FREE HAND SANITIZER is labeled to contain ethyl alcohol 75% v\u002Fv. However, FDA laboratory analysis of batches of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of this product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C 352(e)(1)(A).\n\nIMC WASH-FREE HAND SANITIZER is also misbranded under section 502(x) of the FD&C Act, 21 U.S.C. 352(x) because the product label fails to disclose a complete domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because IMC WASH-FREE HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAdditionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features a statement of identity of the commodity.” Under section 505G(a)(3) of the FD&C Act and the 1994 TFM, the statement of identity for health-care antiseptic drug products, a category that included consumer antiseptic rub drug products, must contain “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel. However, we recommend that you include the name “alcohol gel” as part of the statement of identity that appears on the principal display panel of the label for IMC WASH-FREE HAND SANITIZER which will allow consumers to make an informed decisions regarding your topical antiseptic.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on January 7, 2021, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3017086967 and ATTN: LaKeesha Foster Sifontes.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\ncc:\n\nRegistered US Agent\n\nVizocom ICT LLC\n\n860 Jamacha Rd. Ste. 104\n\nEl Cajon, CA 92019\n\n________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products manufactured at your facility, a review of the purported formulations on the drug product’s labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","Guangdong Kemei Pharmaceutical Technology Co. Ltd.","guangdong-kemei-pharmaceutical-technology-co-ltd-612090-12142021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangdong-kemei-pharmaceutical-technology-co-ltd-612090-12142021","2026-10-26T08:08:51.101706+00:00","2021-12-21","612090","Mr. Jack Chen","2026-08-20T02:18:43.767+00:00","2021-12-14",10,{"510k":212,"classification":213,"enforcement":214,"event":215,"event_backfill":216,"pma":217,"warning_letter":218},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-21T04:00:38.865+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]